Escape	O
of	O
human	O
cytomegalovirus	O
from	O
HLA-DR	B-protein
-restricted	O
CD4	O
(	O
+	O
)	O
T-cell	O
response	O
is	O
mediated	O
by	O
repression	O
of	O
gamma	B-protein
interferon	I-protein
-induced	O
class	B-protein
II	I-protein
transactivator	I-protein
expression	O
.	O

Human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
,	O
a	O
betaherpesvirus	O
,	O
is	O
a	O
pathogen	O
which	O
escapes	O
immune	O
recognition	O
through	O
various	O
mechanisms	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
HCMV	O
down	O
regulates	O
gamma	O
interferon	O
(	O
IFN-gamma	B-protein
)	O
-induced	O
HLA-DR	B-protein
expression	O
in	O
U373	B-cell_line
MG	I-cell_line
astrocytoma	I-cell_line
cells	I-cell_line
due	O
to	O
a	O
defect	O
downstream	O
of	O
STAT1	B-protein
phosphorylation	O
and	O
nuclear	O
translocation	O
.	O

Repression	O
of	O
class	O
II	O
transactivator	O
(	O
CIITA	B-DNA
)	O
mRNA	O
expression	O
is	O
detected	O
within	O
the	O
first	O
hours	O
of	O
IFN-gamma	B-protein
-HCMV	O
coincubation	O
and	O
results	O
in	O
the	O
absence	O
of	O
HLA-DR	B-protein
synthesis	O
.	O

This	O
defect	O
leads	O
to	O
the	O
absence	O
of	O
presentation	O
of	O
the	O
major	B-protein
immediate-early	I-protein
protein	I-protein
IE1	B-protein
to	O
specific	O
CD4	B-cell_line
(	I-cell_line
+	I-cell_line
)	I-cell_line
T-cell	I-cell_line
clones	I-cell_line
when	O
U373	B-cell_line
MG	I-cell_line
cells	I-cell_line
,	O
used	O
as	O
antigen-presenting	B-cell_type
cells	I-cell_type
,	O
are	O
treated	O
with	O
IFN-gamma	B-protein
plus	O
HCMV	O
.	O

However	O
,	O
presentation	O
of	O
endogenously	O
synthesized	O
IE1	B-protein
can	O
be	O
restored	O
when	O
U373	B-cell_line
MG	I-cell_line
cells	I-cell_line
are	O
transfected	O
with	O
CIITA	B-DNA
prior	O
to	O
infection	O
with	O
HCMV	O
.	O

Altogether	O
,	O
the	O
data	O
indicate	O
that	O
the	O
defect	O
induced	O
by	O
HCMV	O
resides	O
in	O
the	O
activation	O
of	O
the	O
IFN-gamma-responsive	B-DNA
promoter	I-DNA
of	O
CIITA	B-DNA
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
viral	O
inhibition	O
of	O
CIITA	B-DNA
expression	O
.	O

JOURNAL	NULL
or	NULL
VirRoLOGY	NULL
,	NULL
Aug.	NULL
1999	NULL
,	NULL
p.	NULL
6582-6589	NULL
0022-538	NULL
X/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

73	NULL
,	NULL
No	NULL
.	NULL

8	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Escape	NULL
of	NULL
Human	NULL
Cytomegalovirus	NULL
from	NULL
HLA-DR-Restricted	NULL
CD4*	NULL
T-Cell	NULL
Response	NULL
Is	NULL
Mediated	NULL
by	NULL
Repression	NULL
of	NULL
Gamma	NULL
Interferon-Induced	NULL
Class	NULL
II	NULL
Transactivator	NULL
Expressiont	NULL
EMMANUELLE	NULL
LE	NULL
ROY	NULL
,	NULL
``	NULL
ANNICK	NULL
MUHLETHALER-MOTTET	NULL
,	NULL
``	NULL
CHRISTIAN	NULL
DAVRINCHE	NULL
,	NULL
'	NULL
BERNARD	NULL
MACH	NULL
,	NULL
``	NULL
anp	NULL
JEAN-LUC	NULL
DAVIGNON	NULL
!	NULL

*	NULL
INSERM	NULL
U	NULL
395	NULL
,	NULL
Toulouse	NULL
,	NULL
France	NULL
,	NULL
and	NULL
Louis	NULL
Jeantet	NULL
Laboratory	NULL
of	NULL
Molecular	NULL
Genetics	NULL
,	NULL
Department	NULL
of	NULL
Genetics	NULL
and	NULL
Microbiology	NULL
,	NULL
University	NULL
of	NULL
Geneva	NULL
Medical	NULL
School	NULL
,	NULL
Geneva	NULL
,	NULL
Switzerland	NULL
``	NULL
Received	NULL
1	NULL
March	NULL
1999/Accepted	NULL
14	NULL
May	NULL
1999	NULL
Human	NULL
cytomegalovirus	NULL
(	NULL
HCMV	NULL
)	NULL
,	NULL
a	NULL
betaherpesvirus	NULL
,	NULL
is	NULL
a	NULL
pathogen	NULL
which	NULL
escapes	NULL
immune	NULL
recognition	NULL
through	NULL
various	NULL
mechanisms	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
show	NULL
that	NULL
HCMV	NULL
down	NULL
regulates	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
-induced	NULL
HLA-DR	NULL
expression	NULL
in	NULL
U373	NULL
MG	NULL
astrocytoma	NULL
cells	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
downstream	NULL
of	NULL
STAT1	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
.	NULL

Repression	NULL
of	NULL
class	NULL
II	NULL
transactivator	NULL
(	NULL
CIITA	NULL
)	NULL
mRNA	NULL
expression	NULL
is	NULL
detected	NULL
within	NULL
the	NULL
first	NULL
hours	NULL
of	NULL
IFN-y-HCMV	NULL
coincubation	NULL
and	NULL
results	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HLA-DR	NULL
synthesis	NULL
.	NULL

This	NULL
defect	NULL
leads	NULL
to	NULL
the	NULL
absence	NULL
of	NULL
presentation	NULL
of	NULL
the	NULL
major	NULL
immediate-early	NULL
protein	NULL
IE1	NULL
to	NULL
specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
when	NULL
U373	NULL
MG	NULL
cells	NULL
,	NULL
used	NULL
as	NULL
antigen-presenting	NULL
cells	NULL
,	NULL
are	NULL
treated	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
.	NULL

However	NULL
,	NULL
presentation	NULL
of	NULL
endogenously	NULL
synthesized	NULL
IE1	NULL
can	NULL
be	NULL
restored	NULL
when	NULL
U373	NULL
MG	NULL
cells	NULL
are	NULL
transfected	NULL
with	NULL
CIHITA	NULL
prior	NULL
to	NULL
infection	NULL
with	NULL
HCMV	NULL
.	NULL

Altogether	NULL
,	NULL
the	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
defect	NULL
induced	NULL
by	NULL
HCMV	NULL
resides	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IFN-y-responsive	NULL
promoter	NULL
of	NULL
This	NULL
is	NULL
the	NULL
first	NULL
demonstration	NULL
of	NULL
a	NULL
viral	NULL
inhibition	NULL
of	NULL
CIITA	NULL
expression	NULL
.	NULL

Human	NULL
cytomegalovirus	NULL
(	NULL
HCMV	NULL
)	NULL
,	NULL
a	NULL
betaherpesvirus	NULL
,	NULL
is	NULL
pathogenic	NULL
almost	NULL
exclusively	NULL
in	NULL
immunocompromised	NULL
individ-uals	NULL
.	NULL

Cellular	NULL
immune	NULL
response	NULL
is	NULL
thought	NULL
to	NULL
control	NULL
HCMV	NULL
in	NULL
immunocompetent	NULL
people	NULL
,	NULL
both	NULL
in	NULL
the	NULL
acute	NULL
phase	NULL
and	NULL
in	NULL
the	NULL
latent	NULL
infection	NULL
which	NULL
ensues	NULL
(	NULL
for	NULL
a	NULL
review	NULL
,	NULL
see	NULL
reference	NULL
6	NULL
)	NULL
.	NULL

Cytotoxic	NULL
CD8*	NULL
T	NULL
cells	NULL
contribute	NULL
greatly	NULL
to	NULL
immunological	NULL
control	NULL
,	NULL
as	NULL
revealed	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
cytotoxic	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
in	NULL
patients	NULL
who	NULL
recover	NULL
from	NULL
acute	NULL
infections	NULL
(	NULL
37	NULL
)	NULL
and	NULL
by	NULL
the	NULL
prevention	NULL
of	NULL
HCMV	NULL
disease	NULL
following	NULL
the	NULL
injection	NULL
of	NULL
viral	NULL
matrix-specific	NULL
CD8	NULL
clones	NULL
to	NULL
bone	NULL
marrow	NULL
transplant	NULL
patients	NULL
(	NULL
44	NULL
)	NULL
.	NULL

CD4*	NULL
T	NULL
cells	NULL
against	NULL
HCMV	NULL
proteins	NULL
have	NULL
also	NULL
been	NULL
described	NULL
(	NULL
4	NULL
,	NULL
12	NULL
,	NULL
28	NULL
)	NULL
,	NULL
and	NULL
a	NULL
significant	NULL
response	NULL
towards	NULL
IE1	NULL
,	NULL
the	NULL
major	NULL
immediate-early	NULL
DNA-binding	NULL
protein	NULL
,	NULL
has	NULL
been	NULL
reported	NULL
(	NULL
3	NULL
,	NULL
9	NULL
)	NULL
.	NULL

The	NULL
precursor	NULL
frequencies	NULL
of	NULL
IE1	NULL
-specific	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
high	NULL
in	NULL
latently	NULL
infected	NULL
individuals	NULL
(	NULL
9	NULL
)	NULL
,	NULL
and	NULL
cytokines	NULL
such	NULL
as	NULL
gamma	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor	NULL
alpha	NULL
(	NULL
TNF-	NULL
«	NULL
)	NULL
found	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
specific	NULL
for	NULL
IE1	NULL
significantly	NULL
reduce	NULL
HCMV	NULL
replication	NULL
(	NULL
10	NULL
)	NULL
.	NULL

The	NULL
role	NULL
of	NULL
CD4~*	NULL
T	NULL
cells	NULL
in	NULL
HCMV	NULL
infections	NULL
was	NULL
inferred	NULL
from	NULL
these	NULL
in	NULL
vitro	NULL
studies	NULL
and	NULL
from	NULL
in	NULL
vivo	NULL
studies	NULL
showing	NULL
that	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
are	NULL
required	NULL
for	NULL
the	NULL
clearance	NULL
of	NULL
mouse	NULL
cytomegalovirus	NULL
(	NULL
MCMV	NULL
)	NULL
in	NULL
salivary	NULL
glands	NULL
of	NULL
mice	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Major	NULL
histocompatibility	NULL
complex	NULL
(	NULL
MHC	NULL
)	NULL
class	NULL
II	NULL
expression	NULL
is	NULL
a	NULL
key	NULL
element	NULL
in	NULL
the	NULL
control	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

It	NULL
is	NULL
required	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
in	NULL
the	NULL
process	NULL
of	NULL
antigen	NULL
(	NULL
Ag	NULL
)	NULL
presentation	NULL
by	NULL
professional	NULL
or	NULL
nonprofessional	NULL
antigen-presenting	NULL
cells	NULL
(	NULL
APC	NULL
)	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Three	NULL
essential	NULL
transacti-vators	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
have	NULL
been	NULL
identified	NULL
:	NULL
RFXS	NULL
and	NULL
RFX-AP	NULL
are	NULL
part	NULL
of	NULL
the	NULL
RFX	NULL
complex	NULL
that	NULL
binds	NULL
to	NULL
the	NULL
X	NULL
box	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
INSERM	NULL
U	NULL
395	NULL
,	NULL
CHU	NULL
Purpan	NULL
,	NULL
BP	NULL
3028	NULL
,	NULL
31024	NULL
Toulouse	NULL
Cedex	NULL
,	NULL
France	NULL
.	NULL

Phone	NULL
:	NULL
33	NULL
5	NULL
62	NULL
74	NULL
83	NULL
76	NULL
.	NULL

Fax	NULL
:	NULL
33	NULL
5	NULL
62	NULL
74	NULL
83	NULL
86	NULL
.	NULL

E-mail	NULL
:	NULL
davignon	NULL
@	NULL
purpan.inserm.fr	NULL
.	NULL

¢	NULL
This	NULL
work	NULL
is	NULL
dedicated	NULL
to	NULL
the	NULL
memory	NULL
of	NULL
our	NULL
friend	NULL
and	NULL
colleague	NULL
Claude	NULL
de	NULL
Préval	NULL
.	NULL

6582	NULL
of	NULL
all	NULL
MHC	NULL
class	NULL
II	NULL
promoters	NULL
,	NULL
while	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
(	NULL
CHTA	NULL
)	NULL
is	NULL
itself	NULL
tightly	NULL
regulated	NULL
,	NULL
and	NULL
this	NULL
transactivator	NULL
functions	NULL
as	NULL
the	NULL
master	NULL
controller	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
,	NULL
probably	NULL
in	NULL
all	NULL
physiological	NULL
conditions	NULL
(	NULL
30	NULL
,	NULL
42	NULL
)	NULL
.	NULL

Both	NULL
constitutive	NULL
and	NULL
inducible	NULL
expressions	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
are	NULL
indeed	NULL
dependent	NULL
on	NULL
CIITA	NULL
,	NULL
and	NULL
the	NULL
CIITA	NULL
gene	NULL
is	NULL
itself	NULL
controlled	NULL
by	NULL
distinct	NULL
alternative	NULL
promoters	NULL
(	NULL
33	NULL
)	NULL
.	NULL

While	NULL
CIITA	NULL
promoters	NULL
I	NULL
and	NULL
III	NULL
are	NULL
specific	NULL
for	NULL
constitutive	NULL
expression	NULL
in	NULL
dendritic	NULL
cells	NULL
and	NULL
B	NULL
lymphocytes	NULL
,	NULL
respectively	NULL
,	NULL
induction	NULL
of	NULL
CIITA	NULL
,	NULL
and	NULL
hence	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
,	NULL
by	NULL
IFN-y	NULL
is	NULL
mediated	NULL
by	NULL
promoter	NULL
IV	NULL
.	NULL

Activation	NULL
by	NULL
IFN-y	NULL
takes	NULL
place	NULL
via	NULL
a	NULL
cascade	NULL
of	NULL
events	NULL
which	NULL
involves	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
STAT1	NULL
by	NULL
JAK1	NULL
and	NULL
JAK2	NULL
kinases	NULL
,	NULL
followed	NULL
by	NULL
nuclear	NULL
translocation	NULL
and	NULL
binding	NULL
of	NULL
STAT1	NULL
to	NULL
a	NULL
GAS	NULL
sequence	NULL
within	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
target	NULL
gene	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
CIITA	NULL
promoter	NULL
IV	NULL
by	NULL
IFN-y	NULL
,	NULL
cooperation	NULL
between	NULL
three	NULL
distinct	NULL
and	NULL
essential	NULL
transacting	NULL
factors	NULL
,	NULL
STAT1	NULL
and	NULL
USF-1	NULL
(	NULL
binding	NULL
cooperatively	NULL
to	NULL
a	NULL
GAS-E	NULL
box	NULL
motif	NULL
)	NULL
and	NULL
IRF-1	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
(	NULL
34	NULL
)	NULL
.	NULL

This	NULL
also	NULL
explains	NULL
why	NULL
JAK1	NULL
and	NULL
STAT1	NULL
mutants	NULL
lack	NULL
induc-ibility	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
by	NULL
IFN-y	NULL
(	NULL
31	NULL
)	NULL
.	NULL

The	NULL
detailed	NULL
dissection	NULL
of	NULL
these	NULL
multiple	NULL
steps	NULL
of	NULL
the	NULL
cascade	NULL
,	NULL
from	NULL
IFN-y	NULL
activation	NULL
to	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
(	NULL
33	NULL
,	NULL
34	NULL
)	NULL
,	NULL
now	NULL
allows	NULL
the	NULL
assignment	NULL
of	NULL
various	NULL
types	NULL
of	NULL
inhibition	NULL
to	NULL
specific	NULL
steps	NULL
within	NULL
this	NULL
cascade	NULL
.	NULL

APC	NULL
capacity	NULL
is	NULL
triggered	NULL
by	NULL
IFN-y	NULL
treatment	NULL
in	NULL
many	NULL
cell	NULL
types	NULL
,	NULL
due	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
expression	NULL
of	NULL
HLA	NULL
class	NULL
II	NULL
,	NULL
the	NULL
invariant	NULL
chain	NULL
,	NULL
and	NULL
HLA-DM	NULL
which	NULL
catalyzes	NULL
the	NULL
release	NULL
of	NULL
invariant	NULL
chain-derived	NULL
Clip	NULL
peptide	NULL
from	NULL
HLA	NULL
class	NULL
II	NULL
molecules	NULL
and	NULL
allows	NULL
the	NULL
binding	NULL
of	NULL
processed	NULL
peptides	NULL
(	NULL
36	NULL
)	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
molecules	NULL
are	NULL
known	NULL
to	NULL
present	NULL
peptides	NULL
derived	NULL
from	NULL
extracellular	NULL
,	NULL
exogenous	NULL
Ag	NULL
to	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
(	NULL
36	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
appears	NULL
that	NULL
presentation	NULL
of	NULL
intracellular	NULL
endogenous	NULL
,	NULL
especially	NULL
viral	NULL
,	NULL
Ags	NULL
is	NULL
common	NULL
(	NULL
14	NULL
,	NULL
23	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
cognate	NULL
interaction	NULL
between	NULL
CD4	NULL
*	NULL
T	NULL
cell	NULL
and	NULL
the	NULL
infected	NULL
MHC	NULL
class	NULL
II-positive	NULL
APC	NULL
.	NULL

Immunological	NULL
controls	NULL
of	NULL
cytomegaloviruses	NULL
are	NULL
counter	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
balanced	NULL
by	NULL
escape	NULL
mechanisms	NULL
from	NULL
class	NULL
I-mediated	NULL
recognition	NULL
by	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
as	NULL
recently	NULL
described	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Several	NULL
genes	NULL
localized	NULL
in	NULL
the	NULL
unique	NULL
short	NULL
(	NULL
US	NULL
)	NULL
region	NULL
of	NULL
the	NULL
HCMV	NULL
genome	NULL
are	NULL
responsible	NULL
for	NULL
down	NULL
regulating	NULL
HLA	NULL
class	NULL
I	NULL
expression	NULL
at	NULL
multiple	NULL
levels	NULL
through	NULL
retrotranslocation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
heavy	NULL
chain	NULL
to	NULL
the	NULL
cytosol	NULL
(	NULL
US2	NULL
[	NULL
19	NULL
,	NULL
47	NULL
]	NULL
and	NULL
US11	NULL
[	NULL
21	NULL
,	NULL
45	NULL
]	NULL
)	NULL
,	NULL
retention	NULL
in	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
(	NULL
US3	NULL
[	NULL
1	NULL
,	NULL
20	NULL
]	NULL
)	NULL
and	NULL
inhibition	NULL
of	NULL
TAP	NULL
translocation	NULL
of	NULL
peptides	NULL
(	NULL
USG	NULL
[	NULL
2	NULL
,	NULL
17	NULL
,	NULL
26	NULL
]	NULL
)	NULL
.	NULL

The	NULL
CD4*	NULL
compartment	NULL
of	NULL
cellular	NULL
immunity	NULL
has	NULL
been	NULL
suspected	NULL
to	NULL
be	NULL
down	NULL
regulated	NULL
since	NULL
the	NULL
observation	NULL
by	NULL
Sedmak	NULL
et	NULL
al	NULL
.	NULL

(	NULL
38	NULL
)	NULL
that	NULL
HCMV	NULL
inhibits	NULL
HLA	NULL
class	NULL
II	NULL
expression	NULL
induced	NULL
by	NULL
IFN-y	NULL
.	NULL

A	NULL
recent	NULL
report	NULL
by	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
has	NULL
described	NULL
a	NULL
mechanism	NULL
of	NULL
JAK1	NULL
proteolysis	NULL
by	NULL
HCMV	NULL
to	NULL
explain	NULL
the	NULL
inhibition	NULL
of	NULL
IFN-y-mediated	NULL
induction	NULL
of	NULL
HLA	NULL
class	NULL
II	NULL
.	NULL

In	NULL
mice	NULL
,	NULL
Heise	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
have	NULL
reported	NULL
that	NULL
MCMV	NULL
down	NULL
regulates	NULL
IFN-y-induced	NULL
expression	NULL
of	NULL
MHC	NULL
class	NULL
I-related	NULL
molecules	NULL
through	NULL
the	NULL
inhibition	NULL
of	NULL
their	NULL
transcription	NULL
.	NULL

The	NULL
mechanism	NULL
,	NULL
which	NULL
occurs	NULL
downstream	NULL
of	NULL
STAT1	NULL
activation	NULL
,	NULL
has	NULL
yet	NULL
to	NULL
be	NULL
determined	NULL
.	NULL

In	NULL
this	NULL
paper	NULL
,	NULL
we	NULL
made	NULL
use	NULL
of	NULL
an	NULL
astrocytoma	NULL
cell	NULL
line	NULL
,	NULL
U373	NULL
MG	NULL
,	NULL
which	NULL
is	NULL
fully	NULL
permissive	NULL
to	NULL
HCMV	NULL
.	NULL

This	NULL
cell	NULL
line	NULL
can	NULL
also	NULL
be	NULL
induced	NULL
to	NULL
express	NULL
HLA-DR	NULL
by	NULL
treatment	NULL
with	NULL
IFN-y	NULL
and	NULL
to	NULL
subsequently	NULL
present	NULL
Ag	NULL
to	NULL
HCMV	NULL
IEl-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
(	NULL
11	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
HCMV	NULL
infection	NULL
prevents	NULL
induction	NULL
of	NULL
HLA-DR	NULL
expression	NULL
by	NULL
IFN-y	NULL
in	NULL
U373	NULL
MG	NULL
cells	NULL
.	NULL

This	NULL
inhibition	NULL
occurs	NULL
downstream	NULL
of	NULL
the	NULL
activation	NULL
of	NULL
STAT1	NULL
,	NULL
whose	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
are	NULL
not	NULL
inhibited	NULL
by	NULL
HCMV	NULL
.	NULL

CIITA	NULL
transcription	NULL
is	NULL
strongly	NULL
repressed	NULL
by	NULL
cotreatment	NULL
of	NULL
cells	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
.	NULL

Logically	NULL
,	NULL
this	NULL
strong	NULL
reduction	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
HCMV	NULL
results	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IE1	NULL
presentation	NULL
and	NULL
recognition	NULL
by	NULL
CD4	NULL
*	NULL
T-cell	NULL
clones	NULL
.	NULL

Transfection	NULL
of	NULL
the	NULL
U373	NULL
MG	NULL
cells	NULL
by	NULL
CIITA	NULL
,	NULL
however	NULL
,	NULL
can	NULL
restore	NULL
both	NULL
HLA-DR	NULL
expression	NULL
and	NULL
the	NULL
ability	NULL
to	NULL
present	NULL
endogenously	NULL
produced	NULL
IE1	NULL
to	NULL
CD4	NULL
*	NULL
T	NULL
cells	NULL
,	NULL
even	NULL
following	NULL
HCMV	NULL
infection	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
,	NULL
in	NULL
IFN-y-treated	NULL
cells	NULL
,	NULL
down	NULL
regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
HCMV	NULL
results	NULL
from	NULL
a	NULL
repression	NULL
of	NULL
CIITA	NULL
induction	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
MHC	NULL
class	NULL
II-dependent	NULL
IE1	NULL
recognition	NULL
by	NULL
viral	NULL
infection	NULL
,	NULL
via	NULL
an	NULL
effect	NULL
on	NULL
CIITA	NULL
expression	NULL
,	NULL
can	NULL
thus	NULL
allow	NULL
HCMV	NULL
cells	NULL
to	NULL
escape	NULL
from	NULL
the	NULL
CD4*	NULL
T-cell	NULL
response	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Virus	NULL
,	NULL
cell	NULL
lines	NULL
,	NULL
and	NULL
the	NULL
IEl-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
.	NULL

HCMV	NULL
(	NULL
Towne	NULL
strain	NULL
)	NULL
stocks	NULL
were	NULL
obtained	NULL
by	NULL
infection	NULL
of	NULL
foreskin	NULL
fibroblasts	NULL
at	NULL
a	NULL
multiplicity	NULL
of	NULL
infection	NULL
(	NULL
MOI	NULL
)	NULL
of	NULL
0.01	NULL
in	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
(	NULL
FCS	NULL
)	NULL
culture	NULL
medium	NULL
(	NULL
RPMI-Glutamax	NULL
I	NULL
supplemented	NULL
with	NULL
sodium	NULL
pyruvate	NULL
and	NULL
antibiotics	NULL
from	NULL
GIBCO-BRL	NULL
)	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
10	NULL
%	NULL
FCS	NULL
culture	NULL
medium	NULL
.	NULL

HCMV	NULL
,	NULL
fibroblasts	NULL
,	NULL
and	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
kind	NULL
gifts	NULL
from	NULL
S.	NULL
Michelson	NULL
(	NULL
Institut	NULL
Pasteur	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Transfection	NULL
of	NULL
U373	NULL
MG	NULL
cells	NULL
with	NULL
the	NULL
pSRa-neo/CIITA-Tag	NULL
plasmid	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
the	NULL
calcium	NULL
phosphate	NULL
method	NULL
.	NULL

Transfected	NULL
cells	NULL
were	NULL
then	NULL
cloned	NULL
by	NULL
limiting	NULL
dilution	NULL
and	NULL
HLA-DR	NULL
expression	NULL
was	NULL
controlled	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

The	NULL
previously	NULL
described	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
FzD3	NULL
specific	NULL
for	NULL
IE1	NULL
was	NULL
obtained	NULL
by	NULL
limiting	NULL
dilution	NULL
from	NULL
a	NULL
healthy	NULL
HCMV-seropositive	NULL
donor	NULL
(	NULL
10	NULL
)	NULL
.	NULL

FzD3	NULL
clone	NULL
was	NULL
maintained	NULL
by	NULL
weekly	NULL
restimulations	NULL
with	NULL
phytohemagglutinin	NULL
and	NULL
allogeneic	NULL
irradiated	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
(	NULL
20	NULL
U/m	NULL
!	NULL
)	NULL

in	NULL
culture	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
human	NULL
serum	NULL
.	NULL

HCMV	NULL
inoculum	NULL
was	NULL
inactivated	NULL
by	NULL
using	NULL
alternating	NULL
UV	NULL
and	NULL
gamma	NULL
irradi-ation	NULL
.	NULL

Both	NULL
were	NULL
used	NULL
to	NULL
ensure	NULL
that	NULL
the	NULL
results	NULL
did	NULL
not	NULL
depend	NULL
on	NULL
the	NULL
inacti-vation	NULL
method	NULL
.	NULL

MAb	NULL
.	NULL

E13	NULL
,	NULL
an	NULL
immunoglobulin	NULL
G1	NULL
(	NULL
IgG1	NULL
)	NULL
mouse	NULL
monoclonal	NULL
antibody	NULL
(	NULL
MAb	NULL
)	NULL
specific	NULL
for	NULL
immediate-early	NULL
proteins	NULL
UL122	NULL
to	NULL
-123	NULL
,	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
M.-C.	NULL
Mazeron	NULL
(	NULL
Hopital	NULL
Lariboisigre	NULL
,	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

MAb	NULL
CCH2	NULL
(	NULL
anti-ULA4	NULL
early	NULL
protein	NULL
)	NULL
was	NULL
purchased	NULL
from	NULL
DAKO	NULL
.	NULL

Control	NULL
IgG1	NULL
myeloma	NULL
protein	NULL
was	NULL
from	NULL
Sigma	NULL
.	NULL

W6/32	NULL
,	NULL
OKT3	NULL
,	NULL
and	NULL
L243	NULL
MAbs	NULL
were	NULL
purchased	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
.	NULL

DA6-231	NULL
,	NULL
an	NULL
anti-HLA-DR	NULL
f	NULL
chain	NULL
(	NULL
43	NULL
)	NULL
,	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
from	NULL
S.	NULL
Demotz	NULL
(	NULL
University	NULL
of	NULL
Lausanne	NULL
,	NULL
Lausanne	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

ESCAPE	NULL
OF	NULL
HCMV	NULL
FROM	NULL
CD4*	NULL
T-CELL	NULL
RESPONSE	NULL
-	NULL
6583	NULL
RNase	NULL
protection	NULL
assays	NULL
.	NULL

Quantitative	NULL
analysis	NULL
of	NULL
CIITA	NULL
and	NULL
GBP	NULL
mRNAs	NULL
was	NULL
performed	NULL
by	NULL
RNase	NULL
protection	NULL
assays	NULL
as	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
30	NULL
)	NULL
.	NULL

Immunoprecipitation	NULL
.	NULL

U373	NULL
MG	NULL
(	NULL
10°	NULL
cells	NULL
)	NULL
was	NULL
plated	NULL
in	NULL
culture	NULL
medium	NULL
in	NULL
25-cm*	NULL
flasks	NULL
and	NULL
was	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
was	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/ml	NULL
)	NULL
,	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/ml	NULL
!	NULL
)	NULL

plus	NULL
HCMV	NULL
(	NULL
MOLI	NULL
=	NULL
5	NULL
)	NULL
,	NULL
or	NULL
incubated	NULL
with	NULL
HCMV	NULL
alone	NULL
(	NULL
MOI	NULL
=	NULL
5	NULL
)	NULL
.	NULL

For	NULL
MHC	NULL
class	NULL
I	NULL
immunoprecipitation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
phosphate-buff-ered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
24	NULL
h	NULL
later	NULL
,	NULL
incubated	NULL
in	NULL
methionine-and-cysteine-free	NULL
medium	NULL
(	NULL
Gibco	NULL
)	NULL
for	NULL
1	NULL
h	NULL
,	NULL
and	NULL
labelled	NULL
with	NULL
[	NULL
*°SJmethionine	NULL
plus	NULL
(	NULL
100	NULL
Ci/	NULL
ml	NULL
)	NULL
(	NULL
ICN	NULL
)	NULL
for	NULL
2	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.05	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
[	NULL
PMSF	NULL
]	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
)	NULL
for	NULL
45	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Preclearing	NULL
of	NULL
the	NULL
lysate	NULL
was	NULL
performed	NULL
overnight	NULL
by	NULL
using	NULL
protein	NULL
A-conjugated	NULL
Sepharose	NULL
beads	NULL
(	NULL
Pharma-cia	NULL
)	NULL
.	NULL

W6/32	NULL
antibody	NULL
was	NULL
then	NULL
added	NULL
to	NULL
the	NULL
lysate	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Protein	NULL
A-coupled	NULL
Sepharose	NULL
beads	NULL
were	NULL
then	NULL
added	NULL
,	NULL
and	NULL
incubation	NULL
was	NULL
continued	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

For	NULL
MHC	NULL
class	NULL
II	NULL
immunoprecipitation	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
18	NULL
h	NULL
after	NULL
treatment	NULL
,	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
in	NULL
methionine-and-cysteine-free	NULL
medium	NULL
and	NULL
labelled	NULL
with	NULL
[	NULL
*°S	NULL
}	NULL
methionine	NULL
plus	NULL
[	NULL
**SJeysteine	NULL
for	NULL
the	NULL
last	NULL
6	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.05	NULL
mM	NULL
PMSF	NULL
,	NULL
50	NULL
mM	NULL
Tris	NULL
[	NULL
pH	NULL
7.6	NULL
]	NULL
)	NULL
for	NULL
45	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

Preclearings	NULL
were	NULL
performed	NULL
as	NULL
follows	NULL
:	NULL
the	NULL
cell	NULL
lysates	NULL
were	NULL
incubated	NULL
with	NULL
normal	NULL
mouse	NULL
serum	NULL
and	NULL
protein	NULL
G-conjugated	NULL
Sepharose	NULL
beads	NULL
for	NULL
2	NULL
h.	NULL
A	NULL
second	NULL
preclearing	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
50	NULL
pil	NULL
of	NULL
zysorbin	NULL
(	NULL
Zymed	NULL
)	NULL
for	NULL
4	NULL
h.	NULL
DA6-231	NULL
antibody	NULL
was	NULL
then	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
lysates	NULL
,	NULL
and	NULL
incubation	NULL
was	NULL
performed	NULL
overnight	NULL
at	NULL
4°C	NULL
.	NULL

Protein	NULL
G-conjugated	NULL
Sepharose	NULL
beads	NULL
were	NULL
then	NULL
added	NULL
,	NULL
and	NULL
incubation	NULL
was	NULL
maintained	NULL
for	NULL
another	NULL
2	NULL
h.	NULL
For	NULL
both	NULL
MHC	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
immunoprecipitations	NULL
,	NULL
the	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
boiled	NULL
in	NULL
5	NULL
%	NULL
B-mercaptocthanol	NULL
reducing	NULL
Laemmli	NULL
buffer	NULL
and	NULL
run	NULL
on	NULL
10	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
.	NULL

Gels	NULL
were	NULL
fixed	NULL
,	NULL
incubated	NULL
in	NULL
Amplify	NULL
(	NULL
Amersham	NULL
)	NULL
,	NULL
vacuum	NULL
dried	NULL
,	NULL
and	NULL
exposed	NULL
to	NULL
hyperfilm-MP	NULL
(	NULL
Amersham	NULL
}	NULL
.	NULL

Flow	NULL
cytometry	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
infected	NULL
by	NULL
using	NULL
supernatant	NULL
from	NULL
infected	NULL
fibroblasts	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/ml	NULL
)	NULL
or	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
or	NULL
IFN-y	NULL
plus	NULL
gamma-irradiated	NULL
HCMV	NULL
.	NULL

The	NULL
contents	NULL
of	NULL
wells	NULL
were	NULL
aspirated	NULL
and	NULL
replaced	NULL
with	NULL
fresh	NULL
medium	NULL
and	NULL
fresh	NULL
IFN-y	NULL
on	NULL
day	NULL
3	NULL
.	NULL

The	NULL
culture	NULL
was	NULL
allowed	NULL
to	NULL
proceed	NULL
for	NULL
an	NULL
additional	NULL
3	NULL
days	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
then	NULL
double	NULL
stained	NULL
for	NULL
cell	NULL
surface	NULL
HLA-DR	NULL
and	NULL
intracellular	NULL
immediate-early	NULL
(	NULL
UL122	NULL
to	NULL
-123	NULL
)	NULL
or	NULL
early	NULL
(	NULL
ULA44	NULL
)	NULL
proteins	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Cell	NULL
viability	NULL
was	NULL
assessed	NULL
by	NULL
using	NULL
Trypan	NULL
Blue	NULL
exclusion	NULL
and	NULL
was	NULL
found	NULL
to	NULL
be	NULL
greater	NULL
than	NULL
80	NULL
%	NULL
.	NULL

For	NULL
double	NULL
staining	NULL
,	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
saturating	NULL
amounts	NULL
of	NULL
OKT3	NULL
(	NULL
used	NULL
as	NULL
a	NULL
control	NULL
)	NULL
or	NULL
L243	NULL
MAb	NULL
in	NULL
Ca**/Mg**-free	NULL
PBS-3	NULL
%	NULL
FCS	NULL
plus	NULL
0.1	NULL
%	NULL
NaN	NULL
,	NULL
(	NULL
staining	NULL
buffer	NULL
)	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
staining	NULL
buffer	NULL
,	NULL
then	NULL
incubated	NULL
with	NULL
goat	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
fragment	NULL
anti-mouse	NULL
IgG	NULL
coupled	NULL
to	NULL
fluorescein	NULL
isothiocyanate	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
staining	NULL
buffer	NULL
,	NULL
then	NULL
incubated	NULL
for	NULL
90	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
OKT3	NULL
to	NULL
saturate	NULL
unbound	NULL
anti-mouse	NULL
IgG-fluorescein	NULL
isothiocyanate	NULL
Fab	NULL
sites	NULL
,	NULL
then	NULL
fixed	NULL
with	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
and	NULL
washed	NULL
with	NULL
PSN	NULL
buffer	NULL
(	NULL
PBS	NULL
+	NULL
1	NULL
%	NULL
normal	NULL
goat	NULL
serum	NULL
+	NULL
1	NULL
mM	NULL
EDTA	NULL
+	NULL
0.05	NULL
%	NULL
saponin	NULL
)	NULL
.	NULL

MAbs	NULL
(	NULL
IgG1	NULL
)	NULL
specific	NULL
for	NULL
HCMV	NULL
immediate-early	NULL
(	NULL
E13	NULL
)	NULL
and	NULL
early	NULL
(	NULL
CCH2	NULL
)	NULL
proteins	NULL
,	NULL
or	NULL
IgG1	NULL
myeloma	NULL
protein	NULL
(	NULL
Sigma	NULL
)	NULL
used	NULL
as	NULL
a	NULL
control	NULL
,	NULL
were	NULL
diluted	NULL
in	NULL
PSN	NULL
,	NULL
and	NULL
added	NULL
to	NULL
cell	NULL
samples	NULL
for	NULL
a	NULL
90-min	NULL
incubation	NULL
at	NULL
37°C	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
PSN	NULL
buffer	NULL
and	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
at	NULL
4°C	NULL
with	NULL
isotype-specific	NULL
phycoerythrin-coupled	NULL
anti-IgG1	NULL
goat	NULL
anti-mouse	NULL
F	NULL
(	NULL
ab	NULL
'	NULL
)	NULL
,	NULL
antiserum	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
analyzed	NULL
by	NULL
using	NULL
an	NULL
EPICS	NULL
Elite	NULL
cell	NULL
sorter	NULL
.	NULL

Immunocytochemistry	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
30,000	NULL
cells	NULL
per	NULL
well	NULL
(	NULL
24-well	NULL
plate	NULL
;	NULL
FALCON	NULL
)	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
heat-inactivated	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
were	NULL
cultured	NULL
for	NULL
24	NULL
h.	NULL
They	NULL
were	NULL
then	NULL
cultured	NULL
in	NULL
serum-free	NULL
medium	NULL
for	NULL
another	NULL
24	NULL
h.	NULL
Then	NULL
they	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/m	NULL
!	NULL
)	NULL

and	NULL
,	NULL
except	NULL
for	NULL
controls	NULL
,	NULL
were	NULL
infected	NULL
with	NULL
HCMV	NULL
for	NULL
15	NULL
or	NULL
30	NULL
min	NULL
or	NULL
1	NULL
,	NULL
6	NULL
,	NULL
or	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
1	NULL
%	NULL
PBS	NULL
and	NULL
were	NULL
fixed	NULL
with	NULL
1	NULL
ml	NULL
of	NULL
1	NULL
%	NULL
PBS	NULL
containing	NULL
3	NULL
%	NULL
paraformaldehyde	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Immunochemistry	NULL
was	NULL
then	NULL
performed	NULL
by	NULL
using	NULL
a	NULL
rabbit	NULL
PhosphoPlus	NULL
STAT1	NULL
(	NULL
Tyr	NULL
701	NULL
)	NULL
antiserum	NULL
(	NULL
Biolabs	NULL
)	NULL
.	NULL

The	NULL
biotinylated	NULL
secondary	NULL
antibody	NULL
was	NULL
a	NULL
peroxidase-coupled	NULL
horse	NULL
anti-mouse	NULL
and	NULL
anti-rabbit	NULL
IgG	NULL
(	NULL
Vectastain	NULL
ABC	NULL
kit	NULL
;	NULL
Vector	NULL
Laboratories	NULL
)	NULL
.	NULL

Staining	NULL
was	NULL
revealed	NULL
by	NULL
using	NULL
diaminobenzidine	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
H	NULL
;	NULL
O	NULL
,	NULL
.	NULL

IE1-specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
response	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
seeded	NULL
at	NULL
1.5	NULL
X	NULL
10°	NULL
cells/well	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
in	NULL
a	NULL
6-well	NULL
plate	NULL
(	NULL
FALCON	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
mock	NULL
infected	NULL
or	NULL
treated	NULL
with	NULL
HCMV	NULL
or	NULL
UV-irradiated	NULL
HCMV	NULL
(	NULL
MOI	NULL
=	NULL
5	NULL
)	NULL
and	NULL
treated	NULL
simultaneously	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/ml	NULL
!	NULL
)	NULL

.	NULL

Cells	NULL
were	NULL
fed	NULL
on	NULL
day	NULL
3	NULL
with	NULL
fresh	NULL
medium	NULL
supplemented	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/ml	NULL
!	NULL
)	NULL

and	NULL
were	NULL
left	NULL
in	NULL
culture	NULL
for	NULL
an	NULL
additional	NULL
2	NULL
days	NULL
.	NULL

U373	NULL
MG-CIITA	NULL
cells	NULL
were	NULL
mock	NULL
infected	NULL
or	NULL
infected	NULL
with	NULL
either	NULL
HCMV	NULL
or	NULL
UV-irradiated	NULL
HCMV	NULL
at	NULL
an	NULL
MOI	NULL
of	NULL
5	NULL
for	NULL
5	NULL
days	NULL
.	NULL

U373	NULL
MG	NULL
and	NULL
U373	NULL
MG-CIITA	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
specific	NULL
IE1	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
91	NULL
to	NULL
110	NULL
)	NULL
(	NULL
Neosystem	NULL
,	NULL
Strasbourg	NULL
,	NULL
France	NULL
)	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
10	NULL
M	NULL
overnight	NULL
.	NULL

U373	NULL
MG	NULL
and	NULL
U373	NULL
MG-CIITA	NULL
cells	NULL
were	NULL
then	NULL
harvested	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
plated	NULL
in	NULL
triplicate	NULL
(	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
well	NULL
)	NULL
in	NULL
a	NULL
96-well	NULL
plate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
3	NULL
x	NULL
10+	NULL
FzD3	NULL
IE1-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
200	NULL
ul	NULL
for	NULL
24	NULL
h.	NULL
Then	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
triplicates	NULL
were	NULL
pooled	NULL
,	NULL
and	NULL
IFN-y	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
an	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
Medgenix	NULL
Screening	NULL
Line	NULL
)	NULL
.	NULL

Western	NULL
blotting	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
(	NULL
10°	NULL
in	NULL
T25	NULL
culture	NULL
flasks	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
culture	NULL
medium	NULL
alone	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
(	NULL
300	NULL
U/m	NULL
!	NULL
)	NULL

or	NULL
IFN-y	NULL
(	NULL
300	NULL
6584	NULL
LE	NULL
ROY	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
B	NULL
1000	NULL
n	NULL
1000	NULL
B	NULL
(	NULL
lee	NULL
,	NULL
I8	NULL
Lge	NULL
UL122-123	NULL
mm-10	NULL
,	NULL
tuo	NULL
1000	NULL
a	NULL
1	NULL
to	NULL
100	NULL
wou	NULL
1800	NULL
w	NULL
1000	NULL
m	NULL
M82	NULL
,	NULL
,	NULL
Pee	NULL
180	NULL
Lcc	NULL
¢	NULL
UL44	NULL
ray	NULL
icin	NULL
map	NULL
Horr	NULL
rtm	NULL
J.	NULL
Virou	NULL
.	NULL

|	NULL
ree	NULL
w	NULL
cdef	NULL
_.	NULL
M	NULL
i	NULL
to	NULL
190	NULL
'	NULL
1088	NULL
a	NULL
2	NULL
IC	NULL
``	NULL
O	NULL
ite	NULL
TB	NULL
1000	NULL
B	NULL
1009	NULL
w	NULL
180	NULL
~	NULL
C	NULL
too-	NULL
u	NULL
-g	NULL
HLA-DR	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
by	NULL
HCMV	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
(	NULL
column	NULL
A	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
IFN-y	NULL
(	NULL
300	NULL
U/m	NULL
!	NULL

1	NULL
)	NULL
(	NULL
column	NULL
B	NULL
)	NULL
,	NULL
treated	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
(	NULL
column	NULL
C	NULL
)	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
IFN-y	NULL
plus	NULL
gamma-irradiated	NULL
HCMV	NULL
(	NULL
column	NULL
D	NULL
)	NULL
,	NULL
as	NULL
indicated	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
then	NULL
double	NULL
stained	NULL
for	NULL
cell	NULL
surface	NULL
HLA-DR	NULL
and	NULL
intracellular	NULL
IE	NULL
(	NULL
upper	NULL
row	NULL
)	NULL
or	NULL
E	NULL
(	NULL
lower	NULL
row	NULL
)	NULL
proteins	NULL
and	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Three	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

U/ml	NULL
!	NULL
)	NULL

plus	NULL
HCMV	NULL
(	NULL
MOLI	NULL
=	NULL
5	NULL
)	NULL
for	NULL
different	NULL
time	NULL
points	NULL
in	NULL
10	NULL
%	NULL
FCS	NULL
culture	NULL
medium	NULL
.	NULL

In	NULL
another	NULL
protocol	NULL
derived	NULL
from	NULL
reference	NULL
32	NULL
,	NULL
cells	NULL
were	NULL
left	NULL
untreated	NULL
,	NULL
treated	NULL
with	NULL
IFN-y	NULL
alone	NULL
,	NULL
or	NULL
treated	NULL
with	NULL
IFN-y	NULL
after	NULL
72	NULL
h	NULL
of	NULL
infection	NULL
by	NULL
HCMV	NULL
.	NULL

The	NULL
incubation	NULL
was	NULL
stopped	NULL
by	NULL
using	NULL
ice-cold	NULL
PBS	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
,	NULL
detached	NULL
with	NULL
a	NULL
cell	NULL
scraper	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
pelleted	NULL
at	NULL
300	NULL
x	NULL
g	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Cells	NULL
were	NULL
lysed	NULL
in	NULL
reducing	NULL
Laemmli	NULL
buffer	NULL
.	NULL

Samples	NULL
equivalent	NULL
to	NULL
3	NULL
X	NULL
10°	NULL
cells	NULL
each	NULL
were	NULL
run	NULL
on	NULL
a	NULL
7.5	NULL
%	NULL
acrylamide	NULL
gel	NULL
and	NULL
transferred	NULL
to	NULL
nitrocellulose	NULL
membranes	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

Membranes	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
rabbit	NULL
PhosphoPlus	NULL
STAT1	NULL
(	NULL
Tyr	NULL
701	NULL
)	NULL
-specific	NULL
antiserum	NULL
(	NULL
Biolabs	NULL
)	NULL
,	NULL
followed	NULL
by	NULL
incubation	NULL
with	NULL
a	NULL
secondary	NULL
peroxidase-coupled	NULL
anti-rabbit	NULL
antiserum	NULL
(	NULL
Biolabs	NULL
)	NULL
.	NULL

Bands	NULL
were	NULL
revealed	NULL
by	NULL
using	NULL
an	NULL
ECL	NULL
detection	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

RESULTS	NULL
Inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
by	NULL
HCMV	NULL
infection	NULL
.	NULL

We	NULL
tested	NULL
the	NULL
induction	NULL
of	NULL
HLA-DR	NULL
by	NULL
IFN-y	NULL
in	NULL
infected	NULL
U373	NULL
MG	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
and	NULL
as	NULL
previously	NULL
shown	NULL
(	NULL
11	NULL
)	NULL
,	NULL
IFN-y	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HCMV	NULL
induced	NULL
high	NULL
levels	NULL
of	NULL
HLA-DR	NULL
expression	NULL
in	NULL
U373	NULL
MG	NULL
cells	NULL
.	NULL

Simultaneous	NULL
coincubation	NULL
of	NULL
HCMV	NULL
with	NULL
IFN-y	NULL
almost	NULL
totally	NULL
prevented	NULL
HLA-DR	NULL
expression	NULL
.	NULL

A	NULL
small	NULL
proportion	NULL
(	NULL
12	NULL
%	NULL
)	NULL
of	NULL
cells	NULL
expressed	NULL
low	NULL
levels	NULL
of	NULL
HLA-DR	NULL
molecules	NULL
in	NULL
spite	NULL
of	NULL
HCMV	NULL
infection	NULL
.	NULL

This	NULL
incomplete	NULL
down	NULL
regulation	NULL
of	NULL
HLA-DR	NULL
by	NULL
HCMV	NULL
was	NULL
observed	NULL
in	NULL
all	NULL
the	NULL
experiments	NULL
performed	NULL
.	NULL

In	NULL
these	NULL
samples	NULL
,	NULL
immediate-early	NULL
(	NULL
UL122	NULL
and	NULL
UL123	NULL
)	NULL
and	NULL
early	NULL
(	NULL
ULA4	NULL
)	NULL
proteins	NULL
were	NULL
detectable	NULL
by	NULL
using	NULL
E13	NULL
and	NULL
CCH2	NULL
MAbs	NULL
,	NULL
respectively	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
,	NULL
when	NULL
U373	NULL
MG	NULL
cells	NULL
are	NULL
incubated	NULL
with	NULL
IFN-y	NULL
and	NULL
HCMV	NULL
simultaneously	NULL
,	NULL
IFN-y	NULL
does	NULL
not	NULL
prevent	NULL
HCMV	NULL
infection	NULL
,	NULL
but	NULL
HCMV	NULL
inhibits	NULL
IFN	NULL
y-induced	NULL
HLA-DR	NULL
expression	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
active	NULL
infection	NULL
accounted	NULL
for	NULL
the	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
,	NULL
HCMV	NULL
was	NULL
gamma	NULL
irradiated	NULL
(	NULL
800	NULL
Gy	NULL
)	NULL
and	NULL
tested	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
.	NULL

Twenty	NULL
percent	NULL
of	NULL
the	NULL
cells	NULL
expressed	NULL
residual	NULL
immediate-early	NULL
proteins	NULL
,	NULL
and	NULL
only	NULL
8	NULL
%	NULL
expressed	NULL
the	NULL
protein	NULL
encoded	NULL
by	NULL
ULA4	NULL
,	NULL
recognized	NULL
by	NULL
CCH2	NULL
antibody	NULL
.	NULL

This	NULL
clearly	NULL
showed	NULL
that	NULL
the	NULL
virus	NULL
was	NULL
inactivated	NULL
.	NULL

Irradiated	NULL
HCMV	NULL
inoculum	NULL
did	NULL
not	NULL
prevent	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
pelleted	NULL
HCMV	NULL
,	NULL
but	NULL
neither	NULL
supernatant	NULL
nor	NULL
UV-irradiated	NULL
HCMV	NULL
,	NULL
repressed	NULL
HLA-DR	NULL
induction	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
neither	NULL
virion-associated	NULL
proteins	NULL
nor	NULL
cytokines	NULL
included	NULL
in	NULL
the	NULL
inoculum	NULL
were	NULL
responsible	NULL
for	NULL
repression	NULL
of	NULL
HLA-DR	NULL
induction	NULL
.	NULL

Inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
synthesis	NULL
by	NULL
HCMV	NULL
infection	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
the	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
expression	NULL
was	NULL
observed	NULL
at	NULL
an	NULL
earlier	NULL
step	NULL
than	NULL
cell	NULL
surface	NULL
expression	NULL
,	NULL
we	NULL
immunoprecipitated	NULL
nascent	NULL
HLA-DR	NULL
molecules	NULL
from	NULL
[	NULL
°°S	NULL
]	NULL
Met-	NULL
[	NULL
~°S	NULL
]	NULL
Cys-labelled	NULL
U373	NULL
MG	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
B-chain-specific	NULL
MAb	NULL
DA6-231	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
a	NULL
24-h	NULL
treatment	NULL
with	NULL
IFN-y	NULL
induced	NULL
the	NULL
appearance	NULL
of	NULL
bands	NULL
which	NULL
correspond	NULL
to	NULL
the	NULL
HLA-DR	NULL
«	NULL
,	NULL
the	NULL
invariant	NULL
,	NULL
and	NULL
the	NULL
HLA-DR	NULL
B	NULL
chains	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
B	NULL
chain	NULL
,	NULL
which	NULL
contains	NULL
fewer	NULL
Met	NULL
and	NULL
Cys	NULL
residues	NULL
than	NULL
the	NULL
«	NULL
and	NULL
invariant	NULL
chains	NULL
,	NULL
was	NULL
less	NULL
labelled	NULL
,	NULL
and	NULL
the	NULL
corresponding	NULL
band	NULL
was	NULL
fainter	NULL
.	NULL

In	NULL
IFN-y	NULL
plus	NULL
HCMV-infected	NULL
cells	NULL
,	NULL
these	NULL
bands	NULL
were	NULL
no	NULL
longer	NULL
de-tected	NULL
.	NULL

This	NULL
result	NULL
confirms	NULL
HCMV	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
expression	NULL
in	NULL
U373	NULL
MG	NULL
cells	NULL
and	NULL
shows	NULL
that	NULL
this	NULL
inhibition	NULL
is	NULL
Vou	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
ESCAPE	NULL
OF	NULL
HCMV	NULL
FROM	NULL
CD4*	NULL
T-CELL	NULL
RESPONSE	NULL
-	NULL
6585	NULL
kDa	NULL
47.5	NULL
-~	NULL
32.5	NULL
-=	NULL
see	NULL
-	NULL
HLA-DR	NULL
&	NULL
chain	NULL
s®-	NULL
_	NULL
Invariant	NULL
chain	NULL
s=	NULL
_	NULL
HLA-DR	NULL
B	NULL
chain	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
B	NULL
chain	NULL
synthesis	NULL
by	NULL
HCMV	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
and/or	NULL
HCMV	NULL
or	NULL
left	NULL
untreated	NULL
for	NULL
18	NULL
h	NULL
and	NULL
were	NULL
pulsed	NULL
with	NULL
*°S	NULL
for	NULL
6	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
HLA-DR	NULL
B	NULL
chain	NULL
synthesis	NULL
was	NULL
analyzed	NULL
by	NULL
immunoprecipitation	NULL
by	NULL
using	NULL
DAG-231	NULL
antibody	NULL
coupled	NULL
to	NULL
Sepharose-protein	NULL
G.	NULL
Three	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

detectable	NULL
at	NULL
the	NULL
level	NULL
of	NULL
protein	NULL
synthesis	NULL
after	NULL
a	NULL
24-h	NULL
cotreatment	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
.	NULL

MHC	NULL
class	NULL
I	NULL
up	NULL
regulation	NULL
by	NULL
IFN-y	NULL
is	NULL
not	NULL
repressed	NULL
by	NULL
HCMV	NULL
.	NULL

To	NULL
test	NULL
whether	NULL
HCMV	NULL
also	NULL
inhibited	NULL
IFN-y-induced	NULL
MHC	NULL
class	NULL
I	NULL
upregulation	NULL
,	NULL
we	NULL
performed	NULL
immunoprecipita-tions	NULL
of	NULL
HLA-A	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-C	NULL
molecules	NULL
by	NULL
using	NULL
W6/32	NULL
MAb	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
,	NULL
and	NULL
as	NULL
expected	NULL
,	NULL
MHC	NULL
class	NULL
I	NULL
protein	NULL
expression	NULL
was	NULL
upregulated	NULL
by	NULL
IFN-y	NULL
.	NULL

This	NULL
up	NULL
regulation	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
HCMV	NULL
concomitant	NULL
infection	NULL
.	NULL

As	NULL
previously	NULL
described	NULL
(	NULL
19	NULL
)	NULL
,	NULL
HLA	NULL
class	NULL
I	NULL
expression	NULL
was	NULL
decreased	NULL
in	NULL
U373	NULL
MG	NULL
cells	NULL
infected	NULL
with	NULL
HCMV	NULL
.	NULL

The	NULL
lack	NULL
of	NULL
effect	NULL
of	NULL
HCMV	NULL
infection	NULL
on	NULL
the	NULL
increase	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
expression	NULL
induced	NULL
by	NULL
IFN-y	NULL
indicates	NULL
a	NULL
clear	NULL
dissociation	NULL
between	NULL
the	NULL
effects	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
Heavy	NULL
Chain	NULL
HCMV	NULL
on	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
and	NULL
MHC	NULL
class	NULL
I	NULL
pathways	NULL
of	NULL
activation	NULL
by	NULL
IFN-y	NULL
.	NULL

Inhibition	NULL
of	NULL
HLA-DR	NULL
synthesis	NULL
is	NULL
not	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
in	NULL
IFN-y-induced	NULL
STAT	NULL
activation	NULL
.	NULL

Since	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
is	NULL
dependent	NULL
upon	NULL
STAT1	NULL
activation	NULL
(	NULL
24	NULL
)	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
STAT1	NULL
phosphorylation	NULL
,	NULL
which	NULL
occurs	NULL
rapidly	NULL
in	NULL
response	NULL
to	NULL
IFN-y	NULL
,	NULL
was	NULL
inhibited	NULL
by	NULL
HCMV	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
and	NULL
in	NULL
accordance	NULL
with	NULL
previous	NULL
reports	NULL
(	NULL
39	NULL
,	NULL
41	NULL
)	NULL
,	NULL
STAT1	NULL
was	NULL
phosphorylated	NULL
after	NULL
as	NULL
little	NULL
as	NULL
15	NULL
min	NULL
of	NULL
IFN-y	NULL
treatment	NULL
.	NULL

Both	NULL
p91	NULL
and	NULL
splice	NULL
variant	NULL
p84	NULL
were	NULL
de-tected	NULL
.	NULL

This	NULL
phosphorylation	NULL
was	NULL
present	NULL
at	NULL
late	NULL
time	NULL
points	NULL
(	NULL
24	NULL
and	NULL
72	NULL
h	NULL
)	NULL
and	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
HCMV	NULL
infection	NULL
at	NULL
a	NULL
time	NULL
point	NULL
(	NULL
24	NULL
h	NULL
)	NULL
when	NULL
HLA-DR	NULL
proteins	NULL
were	NULL
not	NULL
detectable	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Increase	NULL
of	NULL
synthesis	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
proteins	NULL
by	NULL
IFN-y	NULL
in	NULL
HCMV-treated	NULL
U373	NULL
MG	NULL
cells	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
and/or	NULL
HCMV	NULL
or	NULL
left	NULL
untreated	NULL
for	NULL
24	NULL
h	NULL
and	NULL
pulsed	NULL
with	NULL
for	NULL
2	NULL
h.	NULL
Cells	NULL
were	NULL
lysed	NULL
,	NULL
and	NULL
HLA	NULL
class	NULL
I	NULL
synthesis	NULL
was	NULL
measured	NULL
by	NULL
immunoprecipitation	NULL
by	NULL
using	NULL
W6/32	NULL
antibody	NULL
coupled	NULL
to	NULL
Sepharose-protein	NULL
A	NULL
.	NULL

Two	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

6586	NULL
LE	NULL
ROY	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
Time	NULL
72h	NULL
15	NULL
min	NULL
.	NULL

6h	NULL
IFN-y	NULL
-	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
HCMV	NULL
=	NULL
-	NULL
*+	NULL
+	NULL
-	NULL
*+	NULL
+	NULL
STATI-	NULL
P	NULL
-	NULL
p	NULL
91._	NULL
p	NULL
84	NULL
STATL	NULL
-	NULL
p91	NULL
_	NULL
o	NULL
«	NULL
was	NULL
gp	NULL
s***	NULL
D1	NULL
-	NULL
.	NULL

cmt	NULL
«	NULL
tmms	NULL
«	NULL
a	NULL
Time	NULL
24h	NULL
72h	NULL
IFN-y	NULL
+	NULL
+	NULL
-	NULL
+	NULL
+	NULL
HCMV	NULL
=	NULL
+	NULL
+	NULL
=-	NULL
+	NULL
+	NULL
STATI-P	NULL
p91	NULL
_	NULL
i/	NULL
whn	NULL
p	NULL
$	NULL
4	NULL
-|	NULL
eas	NULL
STAT1	NULL
p91—taxman	NULL
?	NULL

mun-mumnm.Ww	NULL
p	NULL
84	NULL
B	NULL
HCMV	NULL
-	NULL
-	NULL
+	NULL
|	NULL
-	NULL
+	NULL
IFN-y	NULL
=	NULL
[	NULL
15	NULL
min	NULL
{	NULL
15	NULL
min	NULL
]	NULL
6h	NULL
|	NULL
66	NULL
P-STATI	NULL
g	NULL
231	NULL
:	NULL
-	NULL
e	NULL
``	NULL
``	NULL
``	NULL
STAT	NULL
p	NULL
91	NULL
__	NULL
Pee	NULL
29	NULL
p	NULL
s-	NULL
--	NULL
-	NULL
®t	NULL
g-	NULL
»	NULL
gas	NULL
aan	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

STAT1	NULL
activation	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
and	NULL
HCMV	NULL
.	NULL

(	NULL
A	NULL
)	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
either	NULL
untreated	NULL
or	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
or	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
for	NULL
15	NULL
min	NULL
and	NULL
6	NULL
,	NULL
24	NULL
,	NULL
and	NULL
72	NULL
h.	NULL
STAT1	NULL
phosphorylation	NULL
was	NULL
evaluated	NULL
in	NULL
a	NULL
Western	NULL
blot	NULL
by	NULL
using	NULL
an	NULL
anti-P-Tyr-STAT1	NULL
specific	NULL
antiserum	NULL
.	NULL

Levels	NULL
of	NULL
STAT1	NULL
protein	NULL
were	NULL
evaluated	NULL
in	NULL
the	NULL
same	NULL
samples	NULL
by	NULL
using	NULL
an	NULL
anti-STAT1	NULL
antiserum	NULL
.	NULL

(	NULL
B	NULL
)	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
either	NULL
incubated	NULL
with	NULL
IFN-y	NULL
for	NULL
15	NULL
min	NULL
or	NULL
6	NULL
h	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
HCMV	NULL
or	NULL
incubated	NULL
with	NULL
IFN-y	NULL
after	NULL
72	NULL
h	NULL
of	NULL
infection	NULL
with	NULL
HCMV	NULL
.	NULL

STAT1	NULL
phosphorylation	NULL
was	NULL
then	NULL
evaluated	NULL
in	NULL
a	NULL
Western	NULL
blot	NULL
by	NULL
using	NULL
an	NULL
anti-P-Tyr-STAT1	NULL
specific	NULL
antiserum	NULL
.	NULL

Levels	NULL
of	NULL
STAT1	NULL
protein	NULL
were	NULL
evaluated	NULL
in	NULL
the	NULL
same	NULL
samples	NULL
by	NULL
using	NULL
an	NULL
anti-STAT1	NULL
antiserum	NULL
.	NULL

Three	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

J.	NULL
Virou	NULL
.	NULL

(	NULL
see	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggested	NULL
that	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
expression	NULL
was	NULL
not	NULL
related	NULL
to	NULL
defects	NULL
in	NULL
STAT1	NULL
phosphorylation	NULL
in	NULL
our	NULL
experimental	NULL
conditions	NULL
.	NULL

However	NULL
,	NULL
STAT1	NULL
phosphorylation	NULL
was	NULL
inhibited	NULL
after	NULL
a	NULL
72-h	NULL
coincubation	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
observed	NULL
when	NULL
we	NULL
used	NULL
foreskin	NULL
fibroblasts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
have	NULL
described	NULL
an	NULL
inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
by	NULL
HCMV	NULL
in	NULL
endothelial	NULL
cells	NULL
and	NULL
fibroblasts	NULL
through	NULL
JAK1	NULL
proteolysis	NULL
,	NULL
which	NULL
logically	NULL
leads	NULL
to	NULL
reduced	NULL
STAT1	NULL
phosphorylation	NULL
.	NULL

These	NULL
observations	NULL
were	NULL
made	NULL
by	NULL
using	NULL
a	NULL
different	NULL
protocol	NULL
,	NULL
consisting	NULL
of	NULL
a	NULL
72-h	NULL
prein-cubation	NULL
with	NULL
HCMV	NULL
before	NULL
IFN-y	NULL
treatment	NULL
.	NULL

Using	NULL
their	NULL
protocol	NULL
,	NULL
we	NULL
also	NULL
observed	NULL
that	NULL
STAT1	NULL
phosphorylation	NULL
was	NULL
inhibited	NULL
after	NULL
15	NULL
min	NULL
and	NULL
6	NULL
h	NULL
of	NULL
IFN-y	NULL
treatment	NULL
in	NULL
U373	NULL
MG-infected	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

This	NULL
shows	NULL
that	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
not	NULL
refractory	NULL
to	NULL
the	NULL
mechanism	NULL
described	NULL
by	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
and	NULL
our	NULL
data	NULL
suggest	NULL
the	NULL
existence	NULL
of	NULL
another	NULL
mechanism	NULL
,	NULL
perhaps	NULL
earlier	NULL
in	NULL
the	NULL
infection	NULL
,	NULL
which	NULL
does	NULL
not	NULL
involve	NULL
the	NULL
inhibition	NULL
of	NULL
STAT1	NULL
phosphorylation	NULL
.	NULL

STAT1	NULL
is	NULL
quickly	NULL
translocated	NULL
to	NULL
the	NULL
nucleus	NULL
after	NULL
phosphorylation	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
U373	NULL
MG	NULL
cells	NULL
,	NULL
nuclear	NULL
translocation	NULL
of	NULL
STAT1	NULL
occurred	NULL
after	NULL
15	NULL
min	NULL
of	NULL
incubation	NULL
with	NULL
IFN-y	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Figure	NULL
5	NULL
shows	NULL
that	NULL
IFN-y-induced	NULL
P-STAT1	NULL
translocation	NULL
to	NULL
the	NULL
nucleus	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
HCMV	NULL
infection	NULL
even	NULL
after	NULL
a	NULL
24-h	NULL
coincubation	NULL
.	NULL

Therefore	NULL
,	NULL
STAT1	NULL
activation	NULL
and	NULL
nuclear	NULL
translocation	NULL
occur	NULL
with	NULL
the	NULL
same	NULL
intensity	NULL
and	NULL
same	NULL
kinetics	NULL
in	NULL
IFN-y-	NULL
and	NULL
IFN-y	NULL
plus	NULL
HCMV-treated	NULL
U373	NULL
MG	NULL
cells	NULL
at	NULL
experimental	NULL
time	NULL
points	NULL
when	NULL
HCMV	NULL
inhibits	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
.	NULL

Repression	NULL
of	NULL
CIITA	NULL
mRNA	NULL
expression	NULL
by	NULL
HCMV	NULL
infection	NULL
.	NULL

Since	NULL
HLA-DR	NULL
repression	NULL
was	NULL
not	NULL
mediated	NULL
by	NULL
a	NULL
defect	NULL
in	NULL
STAT1	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
,	NULL
we	NULL
looked	NULL
for	NULL
an	NULL
inhibition	NULL
further	NULL
down	NULL
the	NULL
pathway	NULL
of	NULL
IFN-y	NULL
signalling	NULL
.	NULL

We	NULL
therefore	NULL
looked	NULL
at	NULL
CIITA	NULL
transcription	NULL
in	NULL
IFN-y-	NULL
and	NULL
IFN-y	NULL
plus	NULL
HCMV-treated	NULL
U373	NULL
MG	NULL
cells	NULL
.	NULL

RNase	NULL
protection	NULL
assays	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
showed	NULL
that	NULL
CIITA	NULL
mRNA	NULL
expression	NULL
was	NULL
induced	NULL
after	NULL
6	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
IFN-y	NULL
,	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
7	NULL
,	NULL
41	NULL
)	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
CIITA	NULL
mRNA	NULL
were	NULL
13.5	NULL
times	NULL
lower	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
than	NULL
in	NULL
cells	NULL
treated	NULL
with	NULL
IFN-y	NULL
alone	NULL
.	NULL

Interestingly	NULL
,	NULL
expression	NULL
of	NULL
the	NULL
GBP	NULL
gene	NULL
,	NULL
which	NULL
is	NULL
also	NULL
up-regulated	NULL
by	NULL
IFN-y	NULL
,	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
HCMV	NULL
(	NULL
ninefold	NULL
decrease	NULL
)	NULL
,	NULL
implying	NULL
a	NULL
mechanism	NULL
common	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
these	NULL
two	NULL
genes	NULL
.	NULL

The	NULL
kinetics	NULL
of	NULL
induction	NULL
of	NULL
CIITA	NULL
by	NULL
IFN-y	NULL
and	NULL
its	NULL
inhibition	NULL
in	NULL
HCMV-infected	NULL
cells	NULL
suggest	NULL
that	NULL
the	NULL
quick	NULL
repression	NULL
of	NULL
CIHITA	NULL
after	NULL
infection	NULL
accounts	NULL
for	NULL
the	NULL
observed	NULL
reduction	NULL
in	NULL
HLA-DR	NULL
expression	NULL
by	NULL
HCMV	NULL
.	NULL

In	NULL
an	NULL
additional	NULL
experiment	NULL
,	NULL
CIITA	NULL
transcription	NULL
was	NULL
found	NULL
to	NULL
be	NULL
still	NULL
repressed	NULL
after	NULL
24	NULL
h	NULL
of	NULL
treatment	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Restoration	NULL
of	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
recognition	NULL
of	NULL
HCMV	NULL
IE1	NULL
by	NULL
constitutive	NULL
CIITA	NULL
expression	NULL
in	NULL
infected	NULL
U373	NULL
MG	NULL
cells	NULL
.	NULL

We	NULL
next	NULL
tested	NULL
the	NULL
consequences	NULL
of	NULL
HLA-DR	NULL
repression	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
specific	NULL
anti-IE1	NULL
T-cell	NULL
clone	NULL
which	NULL
recognizes	NULL
the	NULL
HCMV	NULL
IE1	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
91	NULL
to	NULL
110	NULL
)	NULL
presented	NULL
by	NULL
HLA-DR3-typed	NULL
U373	NULL
MG	NULL
(	NULL
11	NULL
)	NULL
.	NULL

Figure	NULL
7	NULL
shows	NULL
IFN-y	NULL
production	NULL
as	NULL
an	NULL
assay	NULL
for	NULL
activation	NULL
of	NULL
T-cell	NULL
clone	NULL
FzD11	NULL
.	NULL

This	NULL
clone	NULL
produced	NULL
high	NULL
amounts	NULL
of	NULL
IFN-y	NULL
when	NULL
incubated	NULL
with	NULL
IFN-y-treated	NULL
U373	NULL
MG	NULL
cells	NULL
pulsed	NULL
with	NULL
the	NULL
IE1	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
91	NULL
to	NULL
110	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
FzD11	NULL
CD4	NULL
*	NULL
T-cell	NULL
clone	NULL
was	NULL
not	NULL
activated	NULL
by	NULL
U373	NULL
MG	NULL
cells	NULL
infected	NULL
by	NULL
HCMV	NULL
and	NULL
treated	NULL
with	NULL
IFN-y	NULL
for	NULL
5	NULL
days	NULL
.	NULL

This	NULL
was	NULL
not	NULL
due	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
IE1	NULL
production	NULL
since	NULL
high	NULL
levels	NULL
of	NULL
immediate-early	NULL
proteins	NULL
were	NULL
detectable	NULL
in	NULL
this	NULL
protocol	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Figure	NULL
7B	NULL
shows	NULL
that	NULL
the	NULL
FzD11	NULL
clone	NULL
was	NULL
activated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
CIHITA-transfected	NULL
U373	NULL
MG	NULL
cells	NULL
(	NULL
U373	NULL
MG	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
UNTREATED	NULL
IFN-y	NULL
:	NULL
\	NULL
,	NULL
‘	NULL
1	NULL
``	NULL
'	NULL
``	NULL
%	NULL
|	NULL
N	NULL
’	NULL
i	NULL
%	NULL
’	NULL
:	NULL
\	NULL
X	NULL
/	NULL
»	NULL
ﬁ	NULL
‘	NULL
fwu	NULL
JO	NULL
<	NULL
..	NULL
§	NULL
.	NULL

$	NULL
``	NULL
a	NULL
&	NULL
»	NULL
f	NULL
¢	NULL
*	NULL
.	NULL

a	NULL
if	NULL
J	NULL
;	NULL
$	NULL
35	NULL
,	NULL
3	NULL
*=	NULL
R	NULL
A	NULL
;	NULL
42	NULL
j	NULL
:	NULL
o	NULL
k	NULL
f	NULL
cA	NULL
*	NULL
a	NULL
3	NULL
#	NULL
F	NULL
ESCAPE	NULL
OF	NULL
HCMV	NULL
FROM	NULL
CD4*	NULL
T-CELL	NULL
RESPONSE	NULL
6587	NULL
IFN-y	NULL
+	NULL
HCMV	NULL
HemV	NULL
wo	NULL
.	NULL

ep	NULL
;	NULL
gui	NULL
§	NULL
-	NULL
>	NULL
®	NULL
ar	NULL
‘	NULL
5	NULL
,	NULL
h	NULL
*	NULL
»	NULL
[	NULL
'	NULL
>	NULL
s	NULL
#	NULL
a-	NULL
@	NULL
>	NULL
l	NULL
+	NULL
x	NULL
a	NULL
b	NULL
Q	NULL
»	NULL
&	NULL
Rz	NULL
t	NULL
r	NULL
at	NULL
<	NULL
>	NULL
$	NULL
+	NULL
ﬂ	NULL
y	NULL
4	NULL
7	NULL
\	NULL
a	NULL
s	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Nuclear	NULL
translocation	NULL
of	NULL
P-STAT1	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
either	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
were	NULL
incubated	NULL
with	NULL
IFN-y	NULL
,	NULL
HCMV	NULL
,	NULL
or	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
for	NULL
24	NULL
h.	NULL
Nuclear	NULL
localization	NULL
of	NULL
P-STAT1	NULL
was	NULL
evaluated	NULL
by	NULL
immunohistochemistry	NULL
by	NULL
using	NULL
an	NULL
anti-P-STAT1	NULL
specific	NULL
antiserum	NULL
.	NULL

Two	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

CIITA	NULL
cells	NULL
)	NULL
either	NULL
incubated	NULL
with	NULL
the	NULL
IE1	NULL
peptide	NULL
(	NULL
amino	NULL
acids	NULL
91	NULL
to	NULL
110	NULL
)	NULL
or	NULL
infected	NULL
with	NULL
HCMV	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
.	NULL

This	NULL
clone	NULL
was	NULL
not	NULL
activated	NULL
when	NULL
U373	NULL
MG-CIITA	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
UV-irradiated	NULL
virus	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
endogenously	NULL
produced	NULL
IE1	NULL
was	NULL
presented	NULL
during	NULL
HCMV	NULL
infection	NULL
.	NULL

Difference	NULL
of	NULL
IFN-y	NULL
production	NULL
by	NULL
the	NULL
clone	NULL
when	NULL
incubated	NULL
with	NULL
U373	NULL
MG-CIITA	NULL
cells	NULL
infected	NULL
by	NULL
HCMV	NULL
or	NULL
presenting	NULL
IE1	NULL
peptide	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
high	NULL
concentration	NULL
of	NULL
peptide	NULL
used	NULL
(	NULL
10	NULL
LM	NULL
)	NULL
which	NULL
could	NULL
not	NULL
be	NULL
reached	NULL
during	NULL
infection	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
with	NULL
other	NULL
anti-IE1	NULL
CD4	NULL
*	NULL
T-cell	NULL
clones	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
results	NULL
show	NULL
the	NULL
following	NULL
:	NULL
(	NULL
i	NULL
)	NULL
the	NULL
repression	NULL
of	NULL
HLA-DR	NULL
expression	NULL
in	NULL
IFN-y-treated	NULL
U373	NULL
MG	NULL
cells	NULL
affects	NULL
the	NULL
anti-IE1	NULL
CD4+*	NULL
T-cell	NULL
response	NULL
by	NULL
preventing	NULL
the	NULL
presentation	NULL
of	NULL
endogenous	NULL
IE1	NULL
peptide	NULL
;	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
restores	NULL
IE1	NULL
presentation	NULL
by	NULL
infected	NULL
U373	NULL
MG	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
defect	NULL
of	NULL
HLA-DR	NULL
expres-	NULL
IFN-y	NULL
+	NULL
+	NULL
=	NULL
a	NULL
HCMV	NULL
_	NULL
+	NULL
e	NULL
+	NULL
a	NULL
CHTA	NULL
=	NULL
TBP	NULL
=~	NULL
GBP	NULL
=~	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Inhibition	NULL
of	NULL
IFN-y-induced	NULL
CIITA	NULL
transcription	NULL
by	NULL
HCMV	NULL
.	NULL

U373	NULL
MG	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
6	NULL
h	NULL
with	NULL
IFN-y	NULL
,	NULL
HCMV	NULL
,	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
,	NULL
or	NULL
were	NULL
left	NULL
untreated	NULL
in	NULL
culture	NULL
medium	NULL
.	NULL

Quantitative	NULL
expression	NULL
of	NULL
CIITA	NULL
and	NULL
GBP	NULL
mRNA	NULL
was	NULL
examined	NULL
by	NULL
RNase	NULL
protection	NULL
assay	NULL
.	NULL

A	NULL
TBP	NULL
probe	NULL
was	NULL
used	NULL
as	NULL
an	NULL
internal	NULL
control	NULL
.	NULL

Two	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

sion	NULL
due	NULL
to	NULL
HCMV	NULL
occurs	NULL
upstream	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
CHITA	NULL
.	NULL

DISCUSSION	NULL
We	NULL
have	NULL
shown	NULL
in	NULL
this	NULL
paper	NULL
that	NULL
HCMV	NULL
escapes	NULL
from	NULL
CD4	NULL
*	NULL
T-lymphocyte	NULL
recognition	NULL
through	NULL
inhibition	NULL
of	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
.	NULL

The	NULL
inhibition	NULL
is	NULL
mediated	NULL
by	NULL
negative	NULL
regulation	NULL
of	NULL
CIHITA	NULL
transcription	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
report	NULL
of	NULL
virus-mediated	NULL
inhibition	NULL
of	NULL
CIITA	NULL
transcription	NULL
.	NULL

A	NULL
defect	NULL
linked	NULL
with	NULL
viral	NULL
infection	NULL
is	NULL
clearly	NULL
involved	NULL
in	NULL
the	NULL
repression	NULL
of	NULL
HLA-DR	NULL
expression	NULL
.	NULL

This	NULL
was	NULL
concluded	NULL
from	NULL
A	NULL
:	NULL
100000	NULL
10000	NULL
1000	NULL
100	NULL
10	NULL
IFN-	NULL
y	NULL
-treated	NULL
U373	NULL
MG	NULL
100000	NULL
10000	NULL
1000	NULL
100	NULL
10	NULL
IFN-y	NULL
(	NULL
pg/m1	NULL
)	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Restoration	NULL
of	NULL
recognition	NULL
of	NULL
endogenous	NULL
IE1	NULL
by	NULL
specific	NULL
CD4*	NULL
T-cell	NULL
clone	NULL
through	NULL
constitutive	NULL
expression	NULL
of	NULL
CIITA	NULL
.	NULL

Untransfected	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
IFN-y	NULL
and	NULL
UV-inactivated	NULL
or	NULL
unmanipulated	NULL
HCMV	NULL
and	NULL
were	NULL
used	NULL
as	NULL
APC	NULL
in	NULL
T-cell	NULL
specificity	NULL
assays	NULL
of	NULL
IE1-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
.	NULL

Production	NULL
of	NULL
IFN-y	NULL
was	NULL
measured	NULL
(	NULL
A	NULL
)	NULL
.	NULL

CIITA-transfected	NULL
U373	NULL
MG	NULL
cells	NULL
were	NULL
treated	NULL
either	NULL
with	NULL
UV-irradiated	NULL
or	NULL
unmanipulated	NULL
HCMV	NULL
and	NULL
used	NULL
as	NULL
APC	NULL
in	NULL
T-cell	NULL
specificity	NULL
assays	NULL
of	NULL
IEl-specific	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Three	NULL
experiments	NULL
,	NULL
which	NULL
gave	NULL
similar	NULL
results	NULL
,	NULL
were	NULL
performed	NULL
.	NULL

6588	NULL
LE	NULL
ROY	NULL
ET	NULL
AL	NULL
.	NULL

the	NULL
need	NULL
for	NULL
infectious	NULL
virus	NULL
to	NULL
inhibit	NULL
HLA-DR	NULL
induction	NULL
and	NULL
from	NULL
the	NULL
observation	NULL
of	NULL
viral	NULL
protein	NULL
expression	NULL
in	NULL
cells	NULL
with	NULL
repressed	NULL
HLA-DR	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
is	NULL
not	NULL
due	NULL
to	NULL
cytokines	NULL
contained	NULL
in	NULL
the	NULL
viral	NULL
inoculum	NULL
for	NULL
the	NULL
following	NULL
reasons	NULL
:	NULL
first	NULL
,	NULL
irradiated	NULL
virus	NULL
had	NULL
no	NULL
negative	NULL
effect	NULL
on	NULL
IFN-y-induced	NULL
HLA-DR	NULL
expression	NULL
;	NULL
second	NULL
,	NULL
pelleted	NULL
infectious	NULL
virus	NULL
prevented	NULL
HLA-DR	NULL
induction	NULL
effectively	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
;	NULL
third	NULL
,	NULL
the	NULL
amounts	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
HLA-DR	NULL
down	NULL
regulation	NULL
through	NULL
inhibition	NULL
of	NULL
CIITA	NULL
transcription	NULL
(	NULL
25	NULL
,	NULL
35	NULL
)	NULL
,	NULL
were	NULL
found	NULL
to	NULL
be	NULL
similar	NULL
in	NULL
the	NULL
inoculum	NULL
to	NULL
that	NULL
of	NULL
regular	NULL
10	NULL
%	NULL
FCS	NULL
culture	NULL
medium	NULL
(	NULL
300	NULL
pg/ml	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
and	NULL
IFN-B	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
act	NULL
downstream	NULL
of	NULL
CIITA	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Treatment	NULL
of	NULL
cells	NULL
with	NULL
phosphonacetic	NULL
acid	NULL
did	NULL
not	NULL
prevent	NULL
HLA-DR	NULL
inhibition	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
which	NULL
suggests	NULL
that	NULL
the	NULL
viral	NULL
protein	NULL
involved	NULL
is	NULL
encoded	NULL
in	NULL
the	NULL
immediate-early	NULL
and	NULL
early	NULL
phases	NULL
of	NULL
infection	NULL
.	NULL

Besides	NULL
,	NULL
the	NULL
kinetics	NULL
of	NULL
CIITA	NULL
inhibition	NULL
(	NULL
6	NULL
h	NULL
postinfec-tion	NULL
)	NULL
suggest	NULL
that	NULL
the	NULL
repression	NULL
occurs	NULL
in	NULL
the	NULL
immediate-early	NULL
phase	NULL
of	NULL
infection	NULL
.	NULL

However	NULL
,	NULL
this	NULL
point	NULL
needs	NULL
further	NULL
investigation	NULL
to	NULL
help	NULL
identify	NULL
the	NULL
viral	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
involved	NULL
.	NULL

Our	NULL
present	NULL
data	NULL
point	NULL
to	NULL
a	NULL
transcriptional	NULL
modulation	NULL
of	NULL
CIITA	NULL
expression	NULL
due	NULL
to	NULL
viral	NULL
infection	NULL
.	NULL

Therefore	NULL
,	NULL
inhibition	NULL
of	NULL
the	NULL
IFN-y-inducible	NULL
promoter	NULL
IV	NULL
is	NULL
expected	NULL
to	NULL
account	NULL
for	NULL
the	NULL
down	NULL
regulation	NULL
of	NULL
CIITA	NULL
.	NULL

This	NULL
inhibition	NULL
is	NULL
not	NULL
unique	NULL
to	NULL
CIITA	NULL
,	NULL
since	NULL
repression	NULL
of	NULL
both	NULL
CIITA	NULL
and	NULL
GBP	NULL
was	NULL
ob-served	NULL
.	NULL

As	NULL
both	NULL
are	NULL
under	NULL
the	NULL
control	NULL
of	NULL
IRF-1	NULL
(	NULL
5	NULL
,	NULL
34	NULL
)	NULL
,	NULL
which	NULL
is	NULL
itself	NULL
activated	NULL
by	NULL
STAT1	NULL
(	NULL
27	NULL
)	NULL
,	NULL
a	NULL
defect	NULL
in	NULL
IRF-1	NULL
transcription	NULL
or	NULL
in	NULL
its	NULL
binding	NULL
to	NULL
the	NULL
IRF-1	NULL
box	NULL
of	NULL
promoter	NULL
IV	NULL
may	NULL
be	NULL
suspected	NULL
.	NULL

However	NULL
,	NULL
the	NULL
increase	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
synthesis	NULL
induced	NULL
by	NULL
IFN-y	NULL
,	NULL
also	NULL
under	NULL
the	NULL
control	NULL
of	NULL
IRF-1	NULL
(	NULL
18	NULL
)	NULL
,	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
HCMV	NULL
,	NULL
in	NULL
accordance	NULL
with	NULL
a	NULL
previous	NULL
report	NULL
(	NULL
16	NULL
)	NULL
.	NULL

This	NULL
indicates	NULL
uncoupling	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
and	NULL
class	NULL
II	NULL
regulation	NULL
in	NULL
response	NULL
to	NULL
IFN-y	NULL
and	NULL
HCMV	NULL
and	NULL
argues	NULL
against	NULL
a	NULL
major	NULL
role	NULL
of	NULL
IRF-1	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
HLA-DR	NULL
induction	NULL
.	NULL

Alternatively	NULL
,	NULL
functional	NULL
activity	NULL
of	NULL
STAT1	NULL
through	NULL
interaction	NULL
with	NULL
other	NULL
transcriptional	NULL
factors	NULL
such	NULL
as	NULL
USFI1	NULL
(	NULL
34	NULL
)	NULL
may	NULL
be	NULL
impaired	NULL
and	NULL
result	NULL
in	NULL
down	NULL
regulation	NULL
of	NULL
CHITA	NULL
transcription	NULL
.	NULL

Multistep	NULL
inhibitions	NULL
of	NULL
IFN-y-induced	NULL
HLA	NULL
class	NULL
II	NULL
expression	NULL
and	NULL
escape	NULL
from	NULL
CD4	NULL
*	NULL
T-cell	NULL
response	NULL
in	NULL
HCMV	NULL
infection	NULL
are	NULL
likely	NULL
to	NULL
represent	NULL
the	NULL
counterpart	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
inhibition	NULL
of	NULL
expression	NULL
(	NULL
46	NULL
)	NULL
.	NULL

A	NULL
recent	NULL
paper	NULL
by	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
showed	NULL
that	NULL
degradation	NULL
of	NULL
the	NULL
JAK1	NULL
protein	NULL
was	NULL
responsible	NULL
for	NULL
down	NULL
regulation	NULL
of	NULL
HLA-DR	NULL
in	NULL
endothelial	NULL
cells	NULL
.	NULL

Although	NULL
this	NULL
process	NULL
was	NULL
found	NULL
to	NULL
occur	NULL
in	NULL
the	NULL
immediate-early	NULL
or	NULL
early	NULL
phase	NULL
of	NULL
infection	NULL
,	NULL
it	NULL
required	NULL
infection	NULL
of	NULL
the	NULL
cells	NULL
prior	NULL
to	NULL
IFN-y	NULL
treatment	NULL
to	NULL
effectively	NULL
inhibit	NULL
HLA-DR	NULL
induction	NULL
.	NULL

In	NULL
the	NULL
present	NULL
paper	NULL
,	NULL
it	NULL
is	NULL
clear	NULL
that	NULL
the	NULL
impaired	NULL
HLA-DR	NULL
production	NULL
was	NULL
not	NULL
due	NULL
to	NULL
a	NULL
defect	NULL
in	NULL
STAT1	NULL
activation	NULL
.	NULL

Therefore	NULL
,	NULL
our	NULL
protocol	NULL
of	NULL
simultaneous	NULL
coincubation	NULL
of	NULL
IFN-y	NULL
and	NULL
HCMV	NULL
unravels	NULL
a	NULL
new	NULL
mechanism	NULL
of	NULL
HLA-DR	NULL
inhibition	NULL
which	NULL
is	NULL
not	NULL
related	NULL
to	NULL
STAT1	NULL
activation	NULL
,	NULL
since	NULL
STAT1	NULL
phosphorylation	NULL
and	NULL
nuclear	NULL
translocation	NULL
were	NULL
present	NULL
at	NULL
a	NULL
time	NULL
point	NULL
(	NULL
24	NULL
h	NULL
)	NULL
when	NULL
HLA-DR	NULL
protein	NULL
synthesis	NULL
was	NULL
repressed	NULL
.	NULL

Rather	NULL
,	NULL
this	NULL
mechanism	NULL
involves	NULL
the	NULL
inhibition	NULL
of	NULL
CIITA	NULL
RNA	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
U373	NULL
MG	NULL
was	NULL
not	NULL
refractory	NULL
to	NULL
the	NULL
mechanism	NULL
described	NULL
by	NULL
Miller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
since	NULL
we	NULL
observed	NULL
an	NULL
inhibition	NULL
of	NULL
STAT1	NULL
phosphorylation	NULL
when	NULL
their	NULL
protocol	NULL
was	NULL
applied	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
,	NULL
and	NULL
when	NULL
we	NULL
used	NULL
our	NULL
protocol	NULL
,	NULL
STAT1	NULL
phosphorylation	NULL
was	NULL
strongly	NULL
diminished	NULL
after	NULL
72	NULL
h	NULL
of	NULL
cotreatment	NULL
with	NULL
IFN-y	NULL
plus	NULL
HCMV	NULL
.	NULL

We	NULL
conclude	NULL
that	NULL
several	NULL
mechanisms	NULL
can	NULL
account	NULL
for	NULL
the	NULL
diminished	NULL
HLA-DR	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
IFN-y	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
CIITA	NULL
repression	NULL
occurs	NULL
prior	NULL
to	NULL
inhibition	NULL
of	NULL
STAT1	NULL
phosphorylation	NULL
.	NULL

Another	NULL
recent	NULL
report	NULL
showed	NULL
inhibition	NULL
of	NULL
transcription	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
by	NULL
MCMV	NULL
with	NULL
normal	NULL
STAT1	NULL
activation	NULL
(	NULL
15	NULL
)	NULL
J.	NULL
Virou	NULL
.	NULL

similar	NULL
to	NULL
what	NULL
we	NULL
observed	NULL
in	NULL
HCMV	NULL
.	NULL

Whether	NULL
the	NULL
mechanism	NULL
used	NULL
by	NULL
MCMV	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
one	NULL
we	NULL
describe	NULL
in	NULL
the	NULL
present	NULL
report	NULL
remains	NULL
to	NULL
be	NULL
investigated	NULL
.	NULL

Our	NULL
present	NULL
data	NULL
,	NULL
which	NULL
identify	NULL
the	NULL
defect	NULL
in	NULL
CIITA	NULL
gene	NULL
activation	NULL
,	NULL
also	NULL
suggest	NULL
that	NULL
transcription	NULL
of	NULL
other	NULL
genes	NULL
which	NULL
follow	NULL
similar	NULL
regulation	NULL
,	NULL
as	NULL
shown	NULL
for	NULL
GBP	NULL
,	NULL
may	NULL
be	NULL
altered	NULL
by	NULL
HCMV	NULL
infection	NULL
.	NULL

However	NULL
,	NULL
not	NULL
all	NULL
IFN-y-inducible	NULL
genes	NULL
are	NULL
expected	NULL
to	NULL
be	NULL
the	NULL
target	NULL
of	NULL
HCMV	NULL
in	NULL
view	NULL
of	NULL
normal	NULL
up	NULL
regulation	NULL
of	NULL
HLA	NULL
class	NULL
I	NULL
synthesis	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
IFN-y	NULL
and	NULL
HCMV	NULL
.	NULL

The	NULL
mechanism	NULL
involved	NULL
in	NULL
HLA-DR	NULL
down	NULL
regulation	NULL
,	NULL
which	NULL
occurs	NULL
upstream	NULL
of	NULL
CIITA	NULL
and	NULL
downstream	NULL
of	NULL
STAT1	NULL
activation	NULL
,	NULL
suggests	NULL
transcription	NULL
regulation	NULL
by	NULL
an	NULL
immediate-early	NULL
protein	NULL
.	NULL

Current	NULL
studies	NULL
in	NULL
our	NULL
laboratory	NULL
are	NULL
aimed	NULL
at	NULL
identifying	NULL
this	NULL
viral	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
helping	NULL
to	NULL
understand	NULL
HLA	NULL
class	NULL
II	NULL
transcription	NULL
and	NULL
HCMV	NULL
regulation	NULL
of	NULL
transcription	NULL
,	NULL
the	NULL
identification	NULL
of	NULL
such	NULL
a	NULL
protein	NULL
would	NULL
be	NULL
useful	NULL
in	NULL
situations	NULL
where	NULL
targeted	NULL
immunosuppression	NULL
is	NULL
required	NULL
to	NULL
down	NULL
modulate	NULL
exacerbated	NULL
(	NULL
autoimmunity	NULL
)	NULL
or	NULL
nonappropriate	NULL
(	NULL
transplantation	NULL
)	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
.	NULL

Although	NULL
U373	NULL
MG	NULL
cells	NULL
are	NULL
not	NULL
bona	NULL
fide	NULL
APC	NULL
,	NULL
they	NULL
are	NULL
capable	NULL
of	NULL
processing	NULL
and	NULL
presenting	NULL
endogenous	NULL
Ag	NULL
produced	NULL
by	NULL
infected	NULL
cells	NULL
when	NULL
transfected	NULL
with	NULL
CIITA	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
IFN-y	NULL
treatment	NULL
.	NULL

Infection	NULL
of	NULL
cells	NULL
by	NULL
UV-irradiated	NULL
HCMV	NULL
did	NULL
not	NULL
activate	NULL
CD4	NULL
*	NULL
T-cell	NULL
clones	NULL
,	NULL
showing	NULL
that	NULL
IE1	NULL
peptide	NULL
was	NULL
processed	NULL
from	NULL
neosynthesized	NULL
protein	NULL
in	NULL
infected	NULL
U373	NULL
MG-CIITA	NULL
cells	NULL
.	NULL

Presentation	NULL
of	NULL
neosynthesized	NULL
IE1	NULL
and	NULL
cognate	NULL
activation	NULL
of	NULL
infected	NULL
cells	NULL
by	NULL
CD4*	NULL
anti-IE1	NULL
T	NULL
lymphocytes	NULL
has	NULL
not	NULL
been	NULL
documented	NULL
before	NULL
.	NULL

The	NULL
role	NULL
of	NULL
IEl-specific	NULL
CD4*	NULL
T	NULL
cells	NULL
could	NULL
be	NULL
the	NULL
control	NULL
of	NULL
cognate	NULL
,	NULL
infected	NULL
APC	NULL
through	NULL
release	NULL
of	NULL
anti-viral	NULL
cytokines	NULL
such	NULL
as	NULL
IFN-y	NULL
and	NULL
TNF-	NULL
«	NULL
.	NULL

This	NULL
effect	NULL
may	NULL
depend	NULL
on	NULL
the	NULL
cell	NULL
type	NULL
and	NULL
on	NULL
the	NULL
state	NULL
of	NULL
differentiation	NULL
of	NULL
cells	NULL
,	NULL
since	NULL
IFN-y	NULL
and	NULL
TNF-a	NULL
have	NULL
been	NULL
shown	NULL
to	NULL
favor	NULL
the	NULL
differentiation	NULL
and	NULL
infection	NULL
of	NULL
macrophages	NULL
(	NULL
40	NULL
)	NULL
.	NULL

However	NULL
,	NULL
CD4	NULL
*	NULL
T-cell	NULL
clones	NULL
produce	NULL
cytokines	NULL
other	NULL
than	NULL
IFN-y	NULL
and	NULL
TNF-a	NULL
which	NULL
possess	NULL
anti-HCMV	NULL
activity	NULL
and	NULL
may	NULL
reduce	NULL
infection	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
HCMV	NULL
allows	NULL
infected	NULL
cells	NULL
to	NULL
escape	NULL
from	NULL
CD4	NULL
*	NULL
recognition	NULL
by	NULL
blocking	NULL
the	NULL
required	NULL
induction	NULL
of	NULL
HLA-DR	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
,	NULL
using	NULL
U373	NULL
MG	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
,	NULL
that	NULL
HCMV	NULL
escapes	NULL
from	NULL
anti-IE1	NULL
CD4*	NULL
T-lymphocyte	NULL
response	NULL
in	NULL
vitro	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
IFN-y-mediated	NULL
induction	NULL
of	NULL
HLA-DR	NULL
at	NULL
the	NULL
level	NULL
of	NULL
CIITA	NULL
induction	NULL
.	NULL

HCMV	NULL
has	NULL
evolved	NULL
a	NULL
number	NULL
of	NULL
stealth	NULL
mechanisms	NULL
which	NULL
may	NULL
account	NULL
for	NULL
a	NULL
very	NULL
high	NULL
prevalence	NULL
of	NULL
HCMV	NULL
infection	NULL
in	NULL
the	NULL
population	NULL
and	NULL
latency	NULL
in	NULL
immunocompetent	NULL
hosts	NULL
.	NULL

The	NULL
modulation	NULL
of	NULL
the	NULL
anti-IE1	NULL
CD4	NULL
*	NULL
T-cell	NULL
response	NULL
is	NULL
likely	NULL
to	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
host-HCMV	NULL
balance	NULL
.	NULL

Further	NULL
experiments	NULL
are	NULL
needed	NULL
to	NULL
demonstrate	NULL
that	NULL
the	NULL
defect	NULL
we	NULL
describe	NULL
here	NULL
alters	NULL
the	NULL
functional	NULL
CD4*	NULL
T-cell	NULL
response	NULL
in	NULL
acute	NULL
infections	NULL
in	NULL
vivo	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
INSERM	NULL
and	NULL
the	NULL
Association	NULL
pour	NULL
la	NULL
Recherche	NULL
sur	NULL
le	NULL
Cancer	NULL
.	NULL

Emmanuelle	NULL
Le	NULL
Roy	NULL
was	NULL
financed	NULL
by	NULL
an	NULL
M.E.S.R	NULL
.	NULL

fellowship	NULL
.	NULL

We	NULL
thank	NULL
Sanofi	NULL
Elf	NULL
Biorecherche	NULL
for	NULL
the	NULL
gift	NULL
of	NULL
recombinant	NULL
IL-2	NULL
,	NULL
Susan	NULL
Michelson	NULL
and	NULL
Marie-Christine	NULL
Mazeron	NULL
for	NULL
kindly	NULL
supplying	NULL
reagents	NULL
,	NULL
Danitle	NULL
Clément	NULL
for	NULL
technical	NULL
assistance	NULL
,	NULL
and	NULL
Claude	NULL
de	NULL
Préval	NULL
,	NULL
Justine	NULL
Allan	NULL
Yorke	NULL
,	NULL
and	NULL
Paola	NULL
Romagnoli	NULL
for	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Ahn	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Angulo	NULL
,	NULL
P.	NULL
Ghazal	NULL
,	NULL
P.	NULL
A.	NULL
Peterson	NULL
,	NULL
Y.	NULL
Yang	NULL
,	NULL
and	NULL
K.	NULL
Friih	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
cytomegalovirus	NULL
inhibits	NULL
antigen	NULL
presentation	NULL
by	NULL
a	NULL
sequential	NULL
multistep	NULL
process	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:10990-10995	NULL
.	NULL

2	NULL
.	NULL

Abn	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Grubler	NULL
,	NULL
B.	NULL
Galocha	NULL
,	NULL
T.	NULL
R.	NULL
Jones	NULL
,	NULL
E.	NULL
J.	NULL
Wiertz	NULL
,	NULL
H.	NULL
L.	NULL
Ploegh	NULL
,	NULL
P.	NULL
A.	NULL
Peterson	NULL
,	NULL
Y.	NULL
Yang	NULL
,	NULL
and	NULL
K.	NULL
Frubh	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
ER-luminal	NULL
domain	NULL
of	NULL
the	NULL
HCMV	NULL
glycoprotein	NULL
US6	NULL
inhibits	NULL
peptide	NULL
translocation	NULL
by	NULL
TAP	NULL
.	NULL

Immunity	NULL
6:613-621.	NULL
voL	NULL
.	NULL

73	NULL
,	NULL
1999	NULL
3.	NULL
go	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

Alp	NULL
,	NULL
N.	NULL
J.	NULL
,	NULL
T.	NULL
D.	NULL
Allport	NULL
,	NULL
J	NULL
.	NULL

Van	NULL
Zanten	NULL
,	NULL
B.	NULL
Rodgers	NULL
,	NULL
J.	NULL
G.	NULL
Sissons	NULL
,	NULL
and	NULL
L.	NULL
K.	NULL
Borysiewiez	NULL
.	NULL

1991	NULL
.	NULL

Fine	NULL
specificity	NULL
of	NULL
cellular	NULL
immune	NULL
responses	NULL
in	NULL
humans	NULL
to	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
1	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:4812-4820.	NULL
.	NULL

Beninga	NULL
,	NULL
J.	NULL
,	NULL
B.	NULL
Kropff	NULL
,	NULL
and	NULL
M.	NULL
Mach	NULL
.	NULL

1995	NULL
.	NULL

Comparative	NULL
analysis	NULL
of	NULL
fourteen	NULL
individual	NULL
human	NULL
cytomegalovirus	NULL
proteins	NULL
for	NULL
helper	NULL
T	NULL
cell	NULL
response	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

76:153-160.	NULL
.	NULL

Briken	NULL
,	NULL
V.	NULL
,	NULL
H.	NULL
Ruffner	NULL
,	NULL
U.	NULL
Schultz	NULL
,	NULL
A.	NULL
Schwarz	NULL
,	NULL
L.	NULL
F.	NULL
Reis	NULL
,	NULL
I.	NULL
Strehlow	NULL
,	NULL
T.	NULL
Decker	NULL
,	NULL
and	NULL
P.	NULL
Stacheli	NULL
.	NULL

1995	NULL
.	NULL

Interferon	NULL
regulatory	NULL
factor	NULL
1	NULL
is	NULL
required	NULL
for	NULL
mouse	NULL
Gbp	NULL
gene	NULL
activation	NULL
by	NULL
gamma	NULL
interferon	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:975-982.	NULL
.	NULL

Britt	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Alford	NULL
.	NULL

1996	NULL
.	NULL

Cytomegalovirus	NULL
,	NULL
p.	NULL
2493-2523	NULL
.	NULL

In	NULL
B.	NULL
N.	NULL
Fields	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Virology	NULL
,	NULL
3rd	NULL
ed	NULL
.	NULL

Lippincott-Raven	NULL
Publishers	NULL
,	NULL
Philadelphia	NULL
,	NULL
Pa.	NULL
.	NULL

Chang	NULL
,	NULL
C.	NULL
H.	NULL
,	NULL
J.	NULL
D.	NULL
Fontes	NULL
,	NULL
M.	NULL
Peterlin	NULL
,	NULL
and	NULL
R.	NULL
A.	NULL
Flavell	NULL
.	NULL

1994	NULL
.	NULL

Class	NULL
II	NULL
transactivator	NULL
(	NULL
CIITA	NULL
)	NULL
is	NULL
sufficient	NULL
for	NULL
the	NULL
inducible	NULL
expression	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
genes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180:1367-1374.	NULL
.	NULL

Darnell	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Jr.	NULL
1997	NULL
.	NULL

STATs	NULL
and	NULL
gene	NULL
regulation	NULL
.	NULL

Science	NULL
277:1630-1635.	NULL
.	NULL

Davignon	NULL
,	NULL
J.-L.	NULL
,	NULL
D.	NULL
Clement	NULL
,	NULL
J.	NULL
Alriquet	NULL
,	NULL
S.	NULL
Michelson	NULL
,	NULL
and	NULL
C.	NULL
Davrinche	NULL
.	NULL

1995	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
proliferative	NULL
T	NULL
cell	NULL
response	NULL
to	NULL
human	NULL
cytomegalovirus	NULL
major	NULL
immediate-early	NULL
protein	NULL
(	NULL
IE1	NULL
)	NULL
:	NULL
phenotype	NULL
,	NULL
frequency	NULL
and	NULL
variability	NULL
.	NULL

Scand	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

41:247-255	NULL
.	NULL

Davignon	NULL
,	NULL
J.-L.	NULL
,	NULL
P.	NULL
Castanie	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Allan	NULL
Yorke	NULL
,	NULL
N.	NULL
Gautier	NULL
,	NULL
D.	NULL
Clement	NULL
,	NULL
and	NULL
C.	NULL
Davrinche	NULL
.	NULL

1996	NULL
.	NULL

Anti-human	NULL
cytomegalovirus	NULL
activity	NULL
of	NULL
cytokines	NULL
produced	NULL
by	NULL
CD4*	NULL
T-cell	NULL
clones	NULL
specifically	NULL
activated	NULL
by	NULL
IE1	NULL
peptides	NULL
in	NULL
vitro	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

70:2162-2169	NULL
.	NULL

Davignon	NULL
,	NULL
J.-L.	NULL
,	NULL
S.	NULL
Michelson	NULL
,	NULL
and	NULL
C.	NULL
Davrinche	NULL
.	NULL

Presentation	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
immediate-early	NULL
(	NULL
IE1	NULL
)	NULL
protein	NULL
by	NULL
astrocytoma	NULL
cells	NULL
to	NULL
a	NULL
CD4*	NULL
T	NULL
cell	NULL
clone	NULL
,	NULL
p.	NULL
139-144	NULL
.	NULL

In	NULL
S.	NULL
Michelson	NULL
and	NULL
S.	NULL
A.	NULL
Plotkin	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Multidisciplinary	NULL
approach	NULL
to	NULL
understanding	NULL
cytomegalovirus	NULL
disease	NULL
.	NULL

Elsevier	NULL
Science	NULL
Publishing	NULL
,	NULL
Inc.	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Forman	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Zaia	NULL
,	NULL
B.	NULL
R.	NULL
Clark	NULL
,	NULL
C.	NULL
L.	NULL
Wright	NULL
,	NULL
B.	NULL
J	NULL
.	NULL

Mills	NULL
,	NULL
R.	NULL
Pottathil	NULL
,	NULL
B.	NULL
C.	NULL
Racklin	NULL
,	NULL
M.	NULL
T.	NULL
Gallagher	NULL
,	NULL
K.	NULL
Welte	NULL
,	NULL
and	NULL
K.	NULL
G.	NULL
Blume	NULL
.	NULL

1985	NULL
.	NULL

A	NULL
64,000	NULL
dalton	NULL
matrix	NULL
protein	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
induces	NULL
in	NULL
vitro	NULL
immune	NULL
responses	NULL
similar	NULL
to	NULL
those	NULL
of	NULL
whole	NULL
viral	NULL
antigen	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

134:3391-3395	NULL
.	NULL

Germain	NULL
,	NULL
R.	NULL
N.	NULL
1994	NULL
.	NULL

MHC-dependent	NULL
antigen	NULL
processing	NULL
and	NULL
peptide	NULL
pre-sentation	NULL
:	NULL
providing	NULL
ligands	NULL
for	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Cell	NULL
76:287-299	NULL
.	NULL

Gueguen	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
E.	NULL
O	NULL
.	NULL

Long	NULL
.	NULL

1996	NULL
.	NULL

Presentation	NULL
of	NULL
a	NULL
cytosolic	NULL
antigen	NULL
by	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
molecules	NULL
requires	NULL
a	NULL
long-lived	NULL
form	NULL
of	NULL
the	NULL
antigen	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:14692-14697	NULL
.	NULL

Heise	NULL
,	NULL
M.	NULL
T.	NULL
,	NULL
M.	NULL
Connick	NULL
,	NULL
and	NULL
H.	NULL
W.	NULL
Virgin	NULL
IV	NULL
.	NULL

1998	NULL
.	NULL

Murine	NULL
cytomegalovirus	NULL
inhibits	NULL
interferon	NULL
gamma-induced	NULL
antigen	NULL
presentation	NULL
to	NULL
CD4	NULL
T	NULL
cells	NULL
by	NULL
macrophages	NULL
via	NULL
regulation	NULL
of	NULL
expression	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
IT-associated	NULL
genes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:1037-1046	NULL
.	NULL

Hengel	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Esslinger	NULL
,	NULL
J	NULL
.	NULL

Pool	NULL
,	NULL
E.	NULL
Goulmy	NULL
,	NULL
and	NULL
U.	NULL
H.	NULL
Koszinowski	NULL
.	NULL

1995	NULL
.	NULL

Cytokines	NULL
restore	NULL
MHC	NULL
class	NULL
I	NULL
complex	NULL
formation	NULL
and	NULL
control	NULL
antigen	NULL
presentation	NULL
in	NULL
human	NULL
cytomegalovirus-infected	NULL
cells	NULL
.	NULL

J.	NULL
Gen.	NULL
Virol	NULL
.	NULL

76:2987-2997	NULL
.	NULL

Hengel	NULL
,	NULL
H.	NULL
,	NULL
J.	NULL
O.	NULL
Koopmann	NULL
,	NULL
T.	NULL
Flohr	NULL
,	NULL
W.	NULL
Muranyi	NULL
,	NULL
E.	NULL
Goulmy	NULL
,	NULL
G.	NULL
J.	NULL
Hammerling	NULL
,	NULL
U.	NULL
H.	NULL
Koszinowski	NULL
,	NULL
and	NULL
F.	NULL
Momburg	NULL
.	NULL

1997	NULL
.	NULL

A	NULL
viral	NULL
ER-resi-dent	NULL
glycoprotein	NULL
inactivates	NULL
the	NULL
MHC-encoded	NULL
peptide	NULL
transporter	NULL
.	NULL

Immunity	NULL
6:1623-632	NULL
.	NULL

Hobart	NULL
,	NULL
M.	NULL
,	NULL
V.	NULL
Ramassar	NULL
,	NULL
N.	NULL
Goes	NULL
,	NULL
J.	NULL
Urmson	NULL
,	NULL
and	NULL
P.	NULL
F.	NULL
Halloran	NULL
.	NULL

1997	NULL
.	NULL

IFN	NULL
regulatory	NULL
factor-1	NULL
plays	NULL
a	NULL
central	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
expression	NULL
of	NULL
class	NULL
I	NULL
and	NULL
II	NULL
MHC	NULL
genes	NULL
in	NULL
vivo	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:4260-4269	NULL
.	NULL

Jones	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
and	NULL
L.	NULL
Sun	NULL
.	NULL

1997	NULL
.	NULL

Human	NULL
cytomegalovirus	NULL
US2	NULL
destabilizes	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

71:2970-2979	NULL
.	NULL

Jones	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
E.	NULL
J.	NULL
Wiertz	NULL
,	NULL
L.	NULL
Sun	NULL
,	NULL
K.	NULL
N.	NULL
Fish	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
,	NULL
and	NULL
H.	NULL
L.	NULL
Ploegh	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
cytomegalovirus	NULL
US3	NULL
impairs	NULL
transport	NULL
and	NULL
maturation	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:11327-11333	NULL
.	NULL

Jones	NULL
,	NULL
T.	NULL
R.	NULL
,	NULL
L.	NULL
K.	NULL
Hanson	NULL
,	NULL
L.	NULL
Sun	NULL
,	NULL
J.	NULL
S.	NULL
Slater	NULL
,	NULL
R.	NULL
M.	NULL
Stenberg	NULL
,	NULL
and	NULL
A.	NULL
E.	NULL
Campbell	NULL
.	NULL

1995	NULL
.	NULL

Multiple	NULL
independent	NULL
loci	NULL
within	NULL
the	NULL
human	NULL
cytomegalovirus	NULL
unique	NULL
short	NULL
region	NULL
down-regulate	NULL
expression	NULL
of	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

69:4830-4841	NULL
.	NULL

Jonjic	NULL
,	NULL
S.	NULL
,	NULL
W.	NULL
Mutter	NULL
,	NULL
F.	NULL
Weiland	NULL
,	NULL
M.	NULL
J.	NULL
Reddehase	NULL
,	NULL
and	NULL
U.	NULL
H.	NULL
Koszinowski	NULL
.	NULL

1989	NULL
.	NULL

Site-restricted	NULL
persistent	NULL
cytomegalovirus	NULL
infection	NULL
after	NULL
selective	NULL
long-term	NULL
depletion	NULL
of	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169:1199-1212	NULL
.	NULL

Kittlesen	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
L.	NULL
R.	NULL
Brown	NULL
,	NULL
V.	NULL
L.	NULL
Braciale	NULL
,	NULL
J.	NULL
P.	NULL
Sambrook	NULL
,	NULL
M.	NULL
J.	NULL
Gething	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Braciale	NULL
.	NULL

1993	NULL
.	NULL

Presentation	NULL
of	NULL
newly	NULL
synthesized	NULL
glycoproteins	NULL
to	NULL
CD4*	NULL
T	NULL
lymphocytes	NULL
.	NULL

An	NULL
analysis	NULL
using	NULL
influenza	NULL
hemagglutinin	NULL
transport	NULL
mutants	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177:1021-1030	NULL
.	NULL

Lee	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
and	NULL
E.	NULL
N.	NULL
Benveniste	NULL
.	NULL

1996	NULL
.	NULL

Statl	NULL
alpha	NULL
expression	NULL
is	NULL
involved	NULL
in	NULL
IFN-gamma	NULL
induction	NULL
of	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
and	NULL
class	NULL
II	NULL
MHC	NULL
genes	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

157:1559-1568	NULL
.	NULL

Lee	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
Y.	NULL
Han	NULL
,	NULL
H.	NULL
T.	NULL
Lu	NULL
,	NULL
V.	NULL
Nguyen	NULL
,	NULL
H.	NULL
Qin	NULL
,	NULL
P.	NULL
H.	NULL
Howe	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Hocevar	NULL
,	NULL
J.	NULL
M.	NULL
Boss	NULL
,	NULL
R.	NULL
M.	NULL
Ransohoff	NULL
,	NULL
and	NULL
E.	NULL
N.	NULL
Benveniste	NULL
.	NULL

1997	NULL
.	NULL

TGF-beta	NULL
suppresses	NULL
IFN-gamma	NULL
induction	NULL
of	NULL
class	NULL
II	NULL
MHC	NULL
gene	NULL
expression	NULL
by	NULL
inhibiting	NULL
class	NULL
II	NULL
transactivator	NULL
messenger	NULL
RNA	NULL
expression	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:2065-2075	NULL
.	NULL

Lehner	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
J.	NULL
T.	NULL
Karttunen	NULL
,	NULL
G.	NULL
W.	NULL
Wilkinson	NULL
,	NULL
and	NULL
P.	NULL
Cresswell	NULL
.	NULL

1997	NULL
.	NULL

The	NULL
human	NULL
cytomegalovirus	NULL
US6	NULL
glycoprotein	NULL
inhibits	NULL
transporter	NULL
associated	NULL
ESCAPE	NULL
OF	NULL
HCMV	NULL
FROM	NULL
CD4*	NULL
T-CELL	NULL
RESPONSE	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

6589	NULL
with	NULL
antigen	NULL
processing-dependent	NULL
peptide	NULL
translocation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
94:6904-6909	NULL
.	NULL

Li	NULL
,	NULL
X.	NULL
,	NULL
S.	NULL
Leung	NULL
,	NULL
S.	NULL
Qureshi	NULL
,	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Stark	NULL
,	NULL
1996	NULL
.	NULL

Formation	NULL
of	NULL
STAT1-STAT2	NULL
heterodimers	NULL
and	NULL
their	NULL
role	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IRF-1	NULL
gene	NULL
transcription	NULL
by	NULL
interferon-alpha	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:5790-5794	NULL
.	NULL

Liu	NULL
,	NULL
Y.	NULL
N.	NULL
,	NULL
A.	NULL
Klaus	NULL
,	NULL
B.	NULL
Kari	NULL
,	NULL
M.	NULL
F.	NULL
Stinski	NULL
,	NULL
J.	NULL
Eckhardt	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gebhrz	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
N-terminal	NULL
513	NULL
amino	NULL
acids	NULL
of	NULL
the	NULL
envelope	NULL
glycoprotein	NULL
gB	NULL
of	NULL
human	NULL
cytomegalovirus	NULL
stimulates	NULL
both	NULL
B-	NULL
and	NULL
T-cell	NULL
immune	NULL
responses	NULL
in	NULL
humans	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:1644-1648	NULL
.	NULL

Lu	NULL
,	NULL
H.	NULL
T.	NULL
,	NULL
J.	NULL
L.	NULL
Riley	NULL
,	NULL
G.	NULL
T.	NULL
Babcock	NULL
,	NULL
M.	NULL
Huston	NULL
,	NULL
G.	NULL
R.	NULL
Stark	NULL
,	NULL
J.	NULL
M.	NULL
Boss	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Ransohoff	NULL
.	NULL

1995	NULL
.	NULL

Interferon	NULL
(	NULL
IFN	NULL
)	NULL
beta	NULL
acts	NULL
downstream	NULL
of	NULL
IFN-gamma-induced	NULL
class	NULL
II	NULL
transactivator	NULL
messenger	NULL
RNA	NULL
accumulation	NULL
to	NULL
block	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
gene	NULL
expression	NULL
and	NULL
requires	NULL
the	NULL
48-kD	NULL
DNA-binding	NULL
protein	NULL
,	NULL
ISGF3-gamma	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182:1517-1525	NULL
.	NULL

Mach	NULL
,	NULL
B.	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
E.	NULL
Martinez-Soria	NULL
,	NULL
and	NULL
W.	NULL
Reith	NULL
.	NULL

1996	NULL
.	NULL

Regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
genes	NULL
:	NULL
lessons	NULL
from	NULL
a	NULL
disease	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14:301-331	NULL
.	NULL

Meraz	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
J.	NULL
M.	NULL
White	NULL
,	NULL
K.	NULL
C.	NULL
Sheehan	NULL
,	NULL
E.	NULL
A.	NULL
Bach	NULL
,	NULL
S.	NULL
J.	NULL
Rodig	NULL
,	NULL
A.	NULL
S.	NULL
Dighe	NULL
,	NULL
D.	NULL
H.	NULL
Kaplan	NULL
,	NULL
J.	NULL
K.	NULL
Riley	NULL
,	NULL
A.	NULL
C.	NULL
Greenlund	NULL
,	NULL
D.	NULL
Campbell	NULL
,	NULL
K.	NULL
Carver-Moore	NULL
,	NULL
R.	NULL
N.	NULL
DuBois	NULL
,	NULL
R.	NULL
Clark	NULL
,	NULL
M.	NULL
Aguet	NULL
,	NULL
and	NULL
R.	NULL
D.	NULL
Schreiber	NULL
.	NULL

1996	NULL
.	NULL

Targeted	NULL
disruption	NULL
of	NULL
the	NULL
Stat1	NULL
gene	NULL
in	NULL
mice	NULL
reveals	NULL
unexpected	NULL
physiologic	NULL
specificity	NULL
in	NULL
the	NULL
JAK-STAT	NULL
signaling	NULL
pathway	NULL
.	NULL

Cell	NULL
84:431-442	NULL
.	NULL

Miller	NULL
,	NULL
D.	NULL
M.	NULL
,	NULL
B.	NULL
M.	NULL
Rabhill	NULL
,	NULL
J.	NULL
M.	NULL
Boss	NULL
,	NULL
M.	NULL
D.	NULL
Lairmore	NULL
,	NULL
J.	NULL
E.	NULL
Durbin	NULL
,	NULL
J.	NULL
W.	NULL
Waldman	NULL
,	NULL
and	NULL
D.	NULL
D.	NULL
Sedmak	NULL
.	NULL

1998	NULL
.	NULL

Human	NULL
cytomegalovirus	NULL
inhibits	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
disruption	NULL
of	NULL
the	NULL
Jak/Stat	NULL
pathway	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187:675-683	NULL
.	NULL

Mublethaler-Mottet	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
V.	NULL
Steimle	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1997	NULL
.	NULL

Expression	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
in	NULL
different	NULL
cellular	NULL
and	NULL
functional	NULL
compartments	NULL
is	NULL
controlled	NULL
by	NULL
differential	NULL
usage	NULL
of	NULL
multiple	NULL
promoters	NULL
of	NULL
the	NULL
transactivator	NULL
CIITA	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

16:2851-2860	NULL
.	NULL

Mublethaler-Mottet	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
Di	NULL
Berardino	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
CIITA	NULL
by	NULL
interferon-gamma	NULL
requires	NULL
cooperative	NULL
interaction	NULL
between	NULL
Statl	NULL
and	NULL
USF-1	NULL
.	NULL

Immunity	NULL
8:157-166	NULL
.	NULL

Nandan	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
N.	NULL
E.	NULL
Reiner	NULL
.	NULL

1997	NULL
.	NULL

TGF-beta	NULL
attenuates	NULL
the	NULL
class	NULL
II	NULL
transactivator	NULL
and	NULL
reveals	NULL
an	NULL
accessory	NULL
pathway	NULL
of	NULL
IFN-gamma	NULL
action	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

158:1095-1101	NULL
.	NULL

Pieters	NULL
,	NULL
J	NULL
.	NULL

1997	NULL
.	NULL

MHC	NULL
class	NULL
II	NULL
restricted	NULL
antigen	NULL
presentation	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

9:89-96	NULL
.	NULL

Quinnan	NULL
,	NULL
G.	NULL
V.	NULL
,	NULL
Jr.	NULL
,	NULL
N.	NULL
Kirmani	NULL
,	NULL
A.	NULL
H.	NULL
Rook	NULL
,	NULL
J.	NULL
F.	NULL
Manischewitz	NULL
,	NULL
L.	NULL
Jackson	NULL
,	NULL
G.	NULL
Moreschi	NULL
,	NULL
G.	NULL
W.	NULL
Santos	NULL
,	NULL
R.	NULL
Saral	NULL
,	NULL
and	NULL
W.	NULL
H.	NULL
Burns	NULL
.	NULL

1982	NULL
.	NULL

Cytotoxic	NULL
T	NULL
cells	NULL
in	NULL
cytomegalovirus	NULL
infection	NULL
:	NULL
HLA-restricted	NULL
T-lymphocyte	NULL
and	NULL
non-T	NULL
lymphocyte	NULL
cytotoxic	NULL
responses	NULL
correlate	NULL
with	NULL
recovery	NULL
from	NULL
cytomegalovirus	NULL
infection	NULL
in	NULL
bone-marrow-transplant	NULL
recipients	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

307:7-13	NULL
.	NULL

Sedmak	NULL
,	NULL
D.	NULL
D.	NULL
,	NULL
A.	NULL
M.	NULL
Guglielmo	NULL
,	NULL
D.	NULL
A.	NULL
Knight	NULL
,	NULL
D.	NULL
J.	NULL
Birmingham	NULL
,	NULL
E.	NULL
H.	NULL
Huang	NULL
,	NULL
and	NULL
W.	NULL
J.	NULL
Waldman	NULL
.	NULL

1994	NULL
.	NULL

Cytomegalovirus	NULL
inhibits	NULL
major	NULL
histocompatibility	NULL
class	NULL
II	NULL
expression	NULL
on	NULL
infected	NULL
endothelial	NULL
cells	NULL
.	NULL

Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

144:683-692	NULL
.	NULL

Shuai	NULL
,	NULL
K.	NULL
,	NULL
C.	NULL
Schindler	NULL
,	NULL
V.	NULL
R.	NULL
Prezioso	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Darnell	NULL
,	NULL
Jr.	NULL
1992	NULL
.	NULL

Activation	NULL
of	NULL
transcription	NULL
by	NULL
IFN-gamma	NULL
:	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
a	NULL
91-kD	NULL
DNA	NULL
binding	NULL
protein	NULL
.	NULL

Science	NULL
258:1808-1812	NULL
.	NULL

Soderberg-Naucler	NULL
,	NULL
C.	NULL
,	NULL
K.	NULL
N.	NULL
Fish	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Nelson	NULL
.	NULL

1997	NULL
.	NULL

Interferon-gamma	NULL
and	NULL
tumor	NULL
necrosis	NULL
factor-alpha	NULL
specifically	NULL
induce	NULL
formation	NULL
of	NULL
cytomegalovirus-permissive	NULL
monocyte-derived	NULL
macrophages	NULL
that	NULL
are	NULL
refractory	NULL
to	NULL
the	NULL
antiviral	NULL
activity	NULL
of	NULL
these	NULL
cytokines	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Investig	NULL
.	NULL

100:3154-3163	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
C.	NULL
A.	NULL
Siegrist	NULL
,	NULL
A.	NULL
Mottet	NULL
,	NULL
B.	NULL
Lisowska-Grospierre	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1994	NULL
.	NULL

Regulation	NULL
of	NULL
MHC	NULL
class	NULL
II	NULL
expression	NULL
by	NULL
interferon-gamma	NULL
mediated	NULL
by	NULL
the	NULL
transactivator	NULL
gene	NULL
CIITA	NULL
.	NULL

Science	NULL
265:106-109	NULL
.	NULL

Steimle	NULL
,	NULL
V.	NULL
,	NULL
L.	NULL
A.	NULL
Otten	NULL
,	NULL
M.	NULL
Zufferey	NULL
,	NULL
and	NULL
B.	NULL
Mach	NULL
.	NULL

1993	NULL
.	NULL

Complementation	NULL
cloning	NULL
of	NULL
an	NULL
MHC	NULL
class	NULL
II	NULL
transactivator	NULL
mutated	NULL
in	NULL
hereditary	NULL
MHC	NULL
class	NULL
II	NULL
deficiency	NULL
(	NULL
or	NULL
bare	NULL
lymphocyte	NULL
syndrome	NULL
)	NULL
.	NULL

Cell	NULL
75:135-146	NULL
.	NULL

Van	NULL
Heyningen	NULL
,	NULL
V.	NULL
,	NULL
K.	NULL
Guy	NULL
,	NULL
R.	NULL
Newman	NULL
,	NULL
and	NULL
C.	NULL
M.	NULL
Steel	NULL
.	NULL

1982	NULL
.	NULL

Human	NULL
MHC	NULL
class	NULL
II	NULL
molecules	NULL
as	NULL
differentiation	NULL
markers	NULL
.	NULL

Immunogenetics	NULL
16:459-469	NULL
.	NULL

Walter	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
P.	NULL
D.	NULL
Greenberg	NULL
,	NULL
M.	NULL
J.	NULL
Gilbert	NULL
,	NULL
R.	NULL
J.	NULL
Finch	NULL
,	NULL
K.	NULL
S.	NULL
Watanabe	NULL
,	NULL
E.	NULL
D.	NULL
Thomas	NULL
,	NULL
and	NULL
S.	NULL
R.	NULL
Riddell	NULL
.	NULL

1995	NULL
.	NULL

Reconstitution	NULL
of	NULL
cellular	NULL
immunity	NULL
against	NULL
cytomegalovirus	NULL
in	NULL
recipients	NULL
of	NULL
allogeneic	NULL
bone	NULL
marrow	NULL
by	NULL
transfer	NULL
of	NULL
T-cell	NULL
clones	NULL
from	NULL
the	NULL
donor	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

333:1038-1044	NULL
.	NULL

Wiertz	NULL
,	NULL
E.	NULL
J.	NULL
,	NULL
T.	NULL
R.	NULL
Jones	NULL
,	NULL
L.	NULL
Sun	NULL
,	NULL
M.	NULL
Bogyo	NULL
,	NULL
H.	NULL
J.	NULL
Geuze	NULL
,	NULL
and	NULL
H.	NULL
L.	NULL
Ploegh	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
human	NULL
cytomegalovirus	NULL
US11	NULL
gene	NULL
product	NULL
dislocates	NULL
MHC	NULL
class	NULL
I	NULL
heavy	NULL
chains	NULL
from	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
to	NULL
the	NULL
cytosol	NULL
.	NULL

Cell	NULL
84:769-779	NULL
.	NULL

Wiertz	NULL
,	NULL
E.	NULL
,	NULL
A.	NULL
Hill	NULL
,	NULL
D.	NULL
Tortorella	NULL
,	NULL
and	NULL
H.	NULL
Ploegh	NULL
.	NULL

1997	NULL
.	NULL

Cytomegaloviruses	NULL
use	NULL
multiple	NULL
mechanisms	NULL
to	NULL
elude	NULL
the	NULL
host	NULL
immune	NULL
response	NULL
.	NULL

Immunol	NULL
.	NULL

Lett	NULL
.	NULL

57:213-216	NULL
.	NULL

Wiertz	NULL
,	NULL
E.	NULL
,	NULL
D.	NULL
Tortorella	NULL
,	NULL
M.	NULL
Bogyo	NULL
,	NULL
J.	NULL
Yu	NULL
,	NULL
W.	NULL
Mothes	NULL
,	NULL
T.	NULL
R.	NULL
Jones	NULL
,	NULL
T.	NULL
A.	NULL
Rapoport	NULL
,	NULL
and	NULL
H.	NULL
L.	NULL
Ploegh	NULL
.	NULL

1996	NULL
.	NULL

Sec6l-mediated	NULL
transfer	NULL
of	NULL
a	NULL
membrane	NULL
protein	NULL
from	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
to	NULL
the	NULL
proteasome	NULL
for	NULL
destruction	NULL
.	NULL

Nature	NULL
384:432-438	NULL
.	NULL

